Australian Oilseeds Holdings Limited Ordinary Shares (COOT) 10-Q 8 Aug 23 2023 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 08, 2023
Document Information Line Items
Entity Registrant Name	EDOC ACQUISITION CORP.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001824884
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	true
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-39689
Entity Incorporation, State or Country Code	E9
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	7612 Main Street Fishers
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Victor
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	14564
City Area Code	(585)
Local Phone Number	678-1198
Entity Interactive Data Current	Yes
Class A Ordinary Shares
Document Information Line Items
Trading Symbol	ADOC
Entity Common Stock, Shares Outstanding		3,658,377
Title of 12(b) Security	Class A Ordinary Shares, $0.0001 par value per share
Security Exchange Name	NASDAQ
Rights, exchangeable into one-tenth of one Class A Ordinary Share
Document Information Line Items
Trading Symbol	ADOCR
Title of 12(b) Security	Rights, exchangeable into one-tenth of one Class A Ordinary Share
Security Exchange Name	NASDAQ
Warrants, each exercisable for one-half of one Class A Ordinary Share, each whole Warrant exercisable for $11.50 per share
Document Information Line Items
Trading Symbol	ADOCW
Title of 12(b) Security	Warrants, each exercisable for one-half of one Class A Ordinary Share, each whole Warrant exercisable for $11.50 per share
Security Exchange Name	NASDAQ
Class B Ordinary Shares
Document Information Line Items
Entity Common Stock, Shares Outstanding		1

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash	$ 9,558	$ 13,726
Prepaid expenses	69,374	72,386
Total current assets	78,932	86,112
Cash and marketable securities held in Trust Account	9,517,725	21,319,155
Total Assets	9,596,657	21,405,267
Current liabilities:
Accounts payable and accrued expenses	2,525,472	2,151,646
Convertible promissory note – related party, at fair value	1,660,943	1,512,412
Promissory note - related party	1,648,335	702,460
Total current liabilities	5,834,750	4,366,518
Warrant liability	6,706	23,257
Total Liabilities	5,841,456	4,389,775
Commitments and Contingencies (Note 6)
Class A ordinary shares subject to possible redemption, $0.0001 par value; 854,378 and 2,026,625 shares at $11.14 and $10.52 redemption value, respectively, at June 30, 2023 and December 31, 2022	9,517,725	21,319,155
Shareholders’ Deficit
Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding
Class A ordinary shares, $0.0001 par value; 500,000,000 shares authorized; 2,803,999 and 554,000 issued and outstanding at June 30, 2023 and December 31, 2022, respectively (excluding 854,378 and 2,026,625 shares subject to possible redemption at June 30, 2023 and December 31, 2022, respectively)	280	55
Class B ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 1 and 2,250,000 shares issued and outstanding at June 30, 2023 and December 31, 2022		225
Additional paid-in capital	4,579,861	5,332,439
Accumulated deficit	(10,342,665)	(9,636,382)
Total Shareholders’ Deficit	(5,762,524)	(4,303,663)
Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit	$ 9,596,657	$ 21,405,267

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Preferred stock par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Class A Ordinary Shares
Ordinary shares subject to possible redemption, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Ordinary shares subject to possible redemption	854,378	2,026,625
Ordinary shares subject to possible redemption value, per share (in Dollars per share)	$ 11.14	$ 10.52
Ordinary shares, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Ordinary shares, shares authorized	500,000,000	500,000,000
Ordinary shares, shares issued	2,803,999	554,000
Ordinary shares, shares outstanding	2,803,999	554,000
Class B Ordinary Shares
Ordinary shares, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Ordinary shares, shares authorized	50,000,000	50,000,000
Ordinary shares, shares issued	1	2,250,000
Ordinary shares, shares outstanding	1	2,250,000

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Formation and operating costs	$ 265,087	$ 403,445	$ 808,458	$ 1,661,046
Loss from operations	(265,087)	(403,445)	(808,458)	(1,661,046)
Other income (expense):
Interest earned on marketable securities held in Trust Account	86,833	31,044	234,155	35,188
Interest expense	(8,976)	(3,979)	(17,852)	(17,954)
Fair value of shares transferred to backstop investors		(1,529,660)		(4,956,010)
Change in fair value of convertible promissory note	(92,265)	13,452	(130,679)	892
Change in fair value of warrants	4,260	42,156	16,551	184,033
Total other income (expense), net	(10,148)	(1,446,987)	102,175	(4,753,851)
Net Loss	$ (275,235)	$ (1,850,432)	$ (706,283)	$ (6,414,897)
Redeemable Class A Ordinary Shares
Other income (expense):
Weighted average shares outstanding (in Shares)	854,378	2,673,242	1,132,868	4,036,466
Basic and diluted net loss per share (in Dollars per share)	$ (0.08)	$ (0.34)	$ (0.18)	$ (0.94)
Non-Redeemable Class A and Class B Ordinary Shares
Other income (expense):
Weighted average shares outstanding (in Shares)	2,804,000	2,804,000	2,804,000	2,804,000
Basic and diluted net loss per share (in Dollars per share)	$ (0.08)	$ (0.34)	$ (0.18)	$ (0.94)

Condensed Statements of Opera_2

Condensed Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Redeemable Class A Ordinary Shares
Diluted net loss per share	$ (0.08)	$ (0.34)	$ (0.18)	$ (0.94)
Non-Redeemable Class A and Class B Ordinary Shares
Diluted net loss per share	$ (0.08)	$ (0.34)	$ (0.18)	$ (0.94)

Condensed Statements of Changes

Condensed Statements of Changes in Shareholders’ Deficit (Unaudited) - USD ($)	Class A Ordinary Shares	Class B Ordinary Shares	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2021	$ 55	$ 225		$ (1,949,992)	$ (1,949,712)
Balance (in Shares) at Dec. 31, 2021	554,000	2,250,000
Fair value of shares transferred to backstop investors			3,426,350		3,426,350
Remeasurement for ordinary shares to redemption amount			(4,144)		(4,144)
Net loss				(4,564,465)	(4,564,465)
Balance at Mar. 31, 2022	$ 55	$ 225	3,422,206	(6,514,457)	(3,091,971)
Balance (in Shares) at Mar. 31, 2022	554,000	2,250,000
Balance at Dec. 31, 2021	$ 55	$ 225		(1,949,992)	(1,949,712)
Balance (in Shares) at Dec. 31, 2021	554,000	2,250,000
Net loss					(6,414,897)
Balance at Jun. 30, 2022	$ 55	$ 225	4,920,822	(8,364,889)	(3,443,787)
Balance (in Shares) at Jun. 30, 2022	554,000	2,250,000
Balance at Mar. 31, 2022	$ 55	$ 225	3,422,206	(6,514,457)	(3,091,971)
Balance (in Shares) at Mar. 31, 2022	554,000	2,250,000
Fair value of shares transferred to backstop investors			1,529,660		1,529,660
Remeasurement for ordinary shares to redemption amount			(31,044)		(31,044)
Net loss				(1,850,432)	(1,850,432)
Balance at Jun. 30, 2022	$ 55	$ 225	4,920,822	(8,364,889)	(3,443,787)
Balance (in Shares) at Jun. 30, 2022	554,000	2,250,000
Balance at Dec. 31, 2022	$ 55	$ 225	5,332,439	(9,636,382)	(4,303,663)
Balance (in Shares) at Dec. 31, 2022	554,000	2,250,000
Conversion of Class B shares to Class A shares	$ 225	$ (225)
Conversion of Class B shares to Class A shares (in Shares)	2,249,999	(2,249,999)
Remeasurement for ordinary shares to redemption amount			(537,589)		(537,589)
Net loss				(431,048)	(431,048)
Balance at Mar. 31, 2023	$ 280		4,794,850	(10,067,430)	(5,272,300)
Balance (in Shares) at Mar. 31, 2023	2,803,999	1
Balance at Dec. 31, 2022	$ 55	$ 225	5,332,439	(9,636,382)	(4,303,663)
Balance (in Shares) at Dec. 31, 2022	554,000	2,250,000
Net loss					(706,283)
Balance at Jun. 30, 2023	$ 280		4,579,861	(10,342,665)	(5,762,524)
Balance (in Shares) at Jun. 30, 2023	2,803,999	1
Balance at Mar. 31, 2023	$ 280		4,794,850	(10,067,430)	(5,272,300)
Balance (in Shares) at Mar. 31, 2023	2,803,999	1
Remeasurement for ordinary shares to redemption amount			(214,989)		(214,989)
Net loss				(275,235)	(275,235)
Balance at Jun. 30, 2023	$ 280		$ 4,579,861	$ (10,342,665)	$ (5,762,524)
Balance (in Shares) at Jun. 30, 2023	2,803,999	1

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash Flows from Operating Activities:
Net loss	$ (706,283)	$ (6,414,897)
Adjustments to reconcile net loss to net cash used in operating activities:
Interest earned on cash and Treasury securities held in Trust Account	(234,155)	(35,188)
Accrued interest on promissory note	17,852	17,954
Change in fair value of convertible promissory note	130,679	(892)
Change in fair value of warrant liability	(16,551)	(184,033)
Fair value of shares transferred to backstop investors		4,956,010
Changes in operating assets and liabilities:
Prepaid expenses	3,012	(27,993)
Accounts payable and accrued expenses	373,826	939,744
Net cash used in operating activities	(431,620)	(749,295)
Cash Flows from an Investing Activity:
Principal deposited in Trust Account for Trust extension	(517,588)
Interest deposited in Trust account on Trust extension payment	(835)
Cash withdrawn from Trust Account in connection with redemption	12,554,008	64,996,858
Net cash provided by an investing activity	12,035,585	64,996,858
Cash Flows from Financing Activities:
Proceeds from promissory note - related party	945,875
Redemption of Class A ordinary shares	(12,554,008)	(64,996,858)
Proceeds from convertible promissory note - related party		530,000
Net cash used in financing activities	(11,608,133)	(64,466,858)
Net Change in Cash	(4,168)	(219,295)
Cash, beginning of the period	13,726	223,398
Cash, end of period	9,558	4,103
Non-Cash Financing Activity:
Remeasurement for ordinary shares to redemption amount	$ 752,578	$ 35,188

Description of Organization, Bu

Description of Organization, Business Operations, and Going Concern	6 Months Ended
	Jun. 30, 2023
Description of Organization, Business Operations, and Going Concern [Abstract]
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS, AND GOING CONCERN	NOTE 1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS, AND GOING CONCERN EDOC Acquisition Corp. (“Edoc” or the “Company”) was incorporated in the Cayman Islands on August 20, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). While the Company may pursue an acquisition opportunity in any industry or geographic region, the Company intends to focus on businesses primarily operating in the healthcare and healthcare provider space in North America and Asia-Pacific. As of June 30, 2023, the Company had not yet commenced any operations. All activity through June 30, 2023, relates to the Company’s organizational activities, those necessary to prepare for the Initial Public Offering and identifying a target company for the Business Combination. The Company will not generate any operating revenues until after the completion of its initial business combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the IPO. The Company’s sponsor is American Physicians LLC (the “Sponsor”). Financing The registration statement for the Company’s initial public offering was declared effective on November 9, 2020 (the “Effective Date”). On November 12, 2020, the Company consummated the initial public offering of 9,000,000 units (each, a “Unit” and collectively, the “Units”) at $10.00 per Unit (the “Initial Public Offering” or “IPO”), which is discussed in Note 3. Simultaneously with the closing of the IPO, the Company consummated the sale of 479,000 private placement units (“Private Unit)” and collectively, the “Private Units”), at a price of $10.00 per unit. Of the 479,000 private placement units, 65,000 units, or the “representative units” were purchased by I-Banker (and/or its designees). In addition, the Company’s sponsor agreed, pursuant to a letter agreement to purchase up to 3,750,000 of the Company’s rights in the open market at a market price not to exceed $0.20 per right. I-Bankers also agreed to purchase up to 1,250,000 of the Company’s rights in the open market at a market price not to exceed $0.20 per right, which is discussed in Note 5. Transaction costs of the IPO amounted to $3,246,381, consisting of $1,575,000 of cash underwriting fees, the fair value of the representative’s warrants of $424,270, the fair value of representative’s shares $ 653,250 and $593,861 of other cash offering costs. Trust Account Following the closing of the IPO on November 12, 2020, $91,530,000 ($10.17 per Unit) from the net proceeds of the sale of the Units in the IPO and the sale of the Private Warrants was placed in a trust account (“Trust Account”). The funds in the Trust Account are invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of: (i) the completion of a Business Combination, (ii) the redemption of any public shares properly submitted in connection with a shareholder vote to amend the Company’s amended and restated certificate of incorporation, and (iii) the redemption of the Company’s public shares if the Company is unable to complete the initial Business Combination by April 12, 2023 (the “Combination Period”), subject to applicable law. The proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could have priority over the claims of the Company’s public shareholder. On November 9, 2021, the Sponsor requested that the Company extend the date by which the Company has to consummate a Business Combination from November 12, 2021 to February 12, 2022 (the “First Extension”). The Extension was the first of up to two three-month extensions permitted under the Company’s governing documents. On November 10, 2021, $900,000 ($0.10 per share) was added to the Trust Account for the First Extension of the Company. On February 9, 2022, the Company held an extraordinary general meeting pursuant to which the Company’s shareholders approved extending the date by which the Company had to complete a Business Combination from February 12, 2022 to August 12, 2022 (the “Second Extension”). In connection with the approval of the extension, shareholders elected to redeem an aggregate of 6,326,758 Class A ordinary shares. As a result, an aggregate of $64,996,858 (or approximately $10.27 per share) was released from the Trust Account to pay such shareholders. On August 12, 2022, the Company held an extraordinary general meeting pursuant to which the Company’s shareholders approved extending the date by which the Company had to complete a Business Combination from August 12, 2022 to February 12, 2023 (the “Third Extension”). In connection with the approval of the extension, shareholders elected to redeem an aggregate of 646,617 Class A ordinary shares. As a result, an aggregate of $6,660,150 (or approximately $10.30 per share) was released from the Trust Account to pay such shareholders. In connection with this extension of the Company, $202,460 (approximately $0.10 per share) was added to the Trust Account. In connection with the Second Extension of the Company’s termination date from August 12, 2022 to February 12, 2023, $303,994 (approximately $0.15 per share), plus $835 of applicable interest was added to the Trust Account on January 24, 2023. On February 9, 2023, the Company held an extraordinary general meeting in lieu of an annual meeting pursuant to which the Company’s shareholders approved extending the date by which the Company had to complete a Business Combination from February 12, 2023 to August 12, 2023 (the “Fourth Extension”). In connection with the approval of the extension, shareholders elected to redeem an aggregate of 1,172,247 Class A ordinary shares. As a result, an aggregate of $12,554,008 (or approximately $10.71 per share) was released from the Trust Account to pay such shareholders. In connection with the Fourth Extension, $213,595 (approximately $0.10 per share) was added to the Trust Account as of June 30, 2023. Business Combination The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of Private Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (as defined below) (net of amounts disbursed to management for working capital purposes and excluding the amount of any deferred underwriting discount held in trust) at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act 1940, as amended (the “Investment Company Act”). Upon the closing of the IPO, an amount equal to at least $10.00 per Unit sold in the Proposed Public Offering, including the proceeds from the sale of the Private Warrants to the Sponsor, was placed in a trust account (“Trust Account”) located in the United States with Continental Stock Transfer & Trust Company acting as trustee, and invested only in U.S. government securities,” within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below. The Company will provide holders of the Company’s outstanding shares of Class A ordinary shares, par value $0.0001 per share, sold in the IPO (the “Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares (as defined below) upon the completion of the initial Business Combination either (i) in connection with a shareholder meeting called to approve the initial Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a proposed initial Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The shareholders will be entitled to redeem their shares for a pro rata portion of the amount then on deposit in the Trust Account (initially approximately $10.17 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The ordinary shares subject to redemption will be recorded at a redemption value and classified as temporary equity upon the completion of the Proposed Public Offering, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination. Unless further extended, the Company will have until August 12, 2023, to consummate a Business Combination (the “Combination Period”). However, if the Company is unable to complete a Business Combination within the Combination Period, the Company will redeem 100% of the outstanding public shares for a pro rata portion of the funds held in the trust account, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to the Company to pay its income or other tax obligations, divided by the number of then outstanding public shares, subject to applicable law and as further described in registration statement, and then seek to dissolve and liquidate. The Sponsor, officers and directors and Representative (defined in Note 6) have agreed to (i) waive their redemption rights with respect to their founder shares, private shares, and public shares in connection with the completion of the initial Business Combination, (ii) waive their redemption rights with respect to their founder shares, private shares, and public shares in connection with a shareholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation, and (iii) waive their rights to liquidating distributions from the trust account with respect to their founder shares and private shares if the Company fails to complete the initial Business Combination within the Combination Period. The Company’s Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or similar agreement or Business Combination agreement, reduce the amount of funds in the trust account to below the lesser of (i) $10.17 per public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the trust account, if less than $10.17 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of this offering against certain liabilities, including liabilities under the Securities Act. However, the Company has not asked its Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether its Sponsor has sufficient funds to satisfy its indemnity obligations and believe that the Company’s Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure that its Sponsor would be able to satisfy those obligations. Business Combination Agreement On December 5, 2022, EDOC Acquisition Corp., a Cayman Islands exempted corporation (together with its successors, “Edoc”), entered into a Business Combination Agreement (the “Business Combination Agreement”) with Australian Oilseeds Investments Pty Ltd., an Australian proprietary company (the “AOI”), Australian Oilseeds Holdings Limited, upon execution of a joinder agreement to become party to the Business Combination Agreement (a “Joinder”), a to-be-formed Cayman Islands exempted company (“Pubco”), AOI Merger Sub, upon execution of a Joinder, a to-be-formed Cayman Islands exempted company and a wholly-owned subsidiary of Pubco (“Merger Sub”), American Physicians LLC, a Delaware limited liability company (“Purchaser Representative”), in the capacity as the Purchaser Representative thereunder, Gary Seaton, in his capacity as the representative for the Sellers (as defined below) in accordance with the terms and conditions of the Business Combination Agreement (the “Seller Representative”) and each of the holders of AOI’s outstanding capital shares named on Annex I thereto (the “Primary Sellers”), as amended from time to time to include subsequent parties that execute and deliver to Edoc, Pubco and AOI a Joinder (the “Joining Sellers”), and the holders of AOI’s outstanding capital shares who are bound by the provisions of the Business Combination Agreement pursuant the drag-along rights set forth in AOI’s memorandum and articles of association (the “Drag-Along Sellers”, and collectively with the Joining Sellers, the “Sellers”). Pursuant to the Business Combination Agreement, subject to the terms and conditions set forth therein, at the closing of the transactions contemplated by the Business Combination Agreement (the “Closing”), (a) Edoc will merge with and into Merger Sub, with Edoc continuing as the surviving entity (the “Merger”), and with holders of Edoc securities receiving substantially identical securities of Pubco, and (b) immediately prior to the Merger, Pubco will acquire all of the issued and outstanding ordinary shares of AOI (the “Purchased Shares”) from the Sellers in exchange for ordinary shares of Pubco, with AOI becoming a wholly-owned subsidiary of Pubco (the “Share Exchange”, and together with the Merger and the other transactions contemplated by the Business Combination Agreement, the “Transactions”). The total consideration to be paid by Pubco to the Sellers for the Purchased Shares shall be an aggregate number of Pubco ordinary shares (the “Exchange Shares”) with an aggregate value (the “Exchange Consideration”) equal to, without duplication, (i) $190,000,000, plus (or minus if negative) (ii) AOI’s net working capital less a target net working capital of $4,000,000, minus (iii) the aggregate amount of any outstanding indebtedness, net of cash and cash equivalents, of AOI and its subsidiaries, and minus (iv) the amount of any unpaid transaction expenses of AOI, with each Pubco ordinary share to be issued to the Sellers valued at $10.00. On March 31, 2023, the Company, AOI, Pubco, Merger Sub, and the Purchaser Representative entered into that certain First Amendment to the Business Combination Agreement (the “First Amendment”), pursuant to which the Business Combination Agreement was amended to add, as a closing condition, that upon the closing of the transactions contemplated by the Business Combination Agreement, the Company shall have cash and cash equivalents, including funds remaining in the Company’s trust account (after giving effect to the completion and payment of the redemption) and the proceeds of any PIPE Investment, prior to giving effect to the payment of the Company’s unpaid expenses or liabilities, of at least equal to $10,000,000. Risks and Uncertainties Management is currently evaluating the impact of the COVID-19 pandemic and Russia-Ukraine war on the industry and has concluded that while it is reasonably possible that the virus and the war could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these interim unaudited condensed financial statements. The interim unaudited condensed financial statements do not include any adjustments that might results from the outcome of these uncertainties. Going Concern As of June 30, 2023, the Company had $9,558 in the operating bank account and working capital deficit of $5,777,448. On November 10, 2021, the Company issued an interest-bearing convertible promissory to the Sponsor in the amount of $900,000. As of June 30, 2023, $900,000 was drawn on the note and the fair value of the note outstanding, including accrued interest of $58,981, was $958,981. On February 13, 2022, the Company issued a non-interest-bearing convertible promissory note in the principal amount of up to $750,000 to the Sponsor. As of June 30, 2023, $750,000 was drawn on the note and the fair value of the note outstanding was $701,962. On August 25, 2022, the Company issued a non-interest-bearing promissory note in the aggregate principal amount of up to $202,460 to the Sponsor. As of June 30, 2023, $202,460 was drawn on the note. On October 6, 2022, the Company issued a non-interest-bearing promissory note in the aggregate principal amount of up to $500,000 to the Sponsor. As of June 30, 2023, $500,000 was drawn on the note. On November 16, 2022, the Company issued a non-interest-bearing promissory note in the aggregate amount of up to $303,994 to the Sponsor. As of June 30, 2023, $303,994 was drawn on the note. On January 10, 2023, the Company issued a non-interest-bearing promissory note in the aggregate amount of up to $450,000 to the Sponsor. As of June 30, 2023, $276,006 was drawn on the note. On February 14, 2023, the Company issued a non-interest-bearing promissory note in the aggregate amount of up to $256,313 to the Sponsor. As of June 30, 2023, $170,876 was drawn on the note. On April 25, 2023, the Company issued a non-interest bearing promissory note in the principal amount of up to $175,000 to the Sponsor. As of June 30, 2023, $175,000 was drawn on the note. On June 26, 2023, the Company issued a non-interest bearing promissory note in the principal amount of up to $250,000 to the Sponsor. As of June 30, 2023, $20,000 was drawn on the note. Until the consummation of a Business Combination, the Company will be using the funds not held in the Trust Account for identifying and evaluating prospective acquisition candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to acquire, and structuring, negotiating and consummating the Business Combination. The Company will need to raise additional capital through loans or additional investments from its Sponsor, shareholders, officers, directors, or third parties. The Company’s Sponsor, officers and directors may, but are not obligated to, loan the Company funds from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. In connection with the Company’s assessment of going concern considerations in accordance with the Financial Accounting Standards Board’s (“FASB’s”) Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that if the Company is unable to raise additional funds to alleviate liquidity needs as well as complete a Business Combination by August 12, 2023 then the Company will cease all operations except for the purpose of liquidating. The liquidity condition and the date for mandatory liquidation and subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern. These interim unaudited condensed financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC on January 24, 2023, which contains the audited financial statements and notes thereto. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging the growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s unaudited condensed financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts or mutual fund accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. As of June 30, 2023 and December 31, 2022, the Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Use of Estimates The preparation of unaudited condensed financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities during the reporting period and the reported amounts of expenses during the reporting period. One of the more significant accounting estimates included in these unaudited condensed financial statements is the determination of the fair value of the warrant liabilities as well as the fair value of the convertible notes. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of June 30, 2023 and December 31, 2022. Investment Held in Trust Account As of June 30, 2023, all of the assets held in the Trust account were held in cash. As of December 31, 2022, substantially all of assets held in the Trust Account were held in money market funds which are invested primarily in U.S. Treasury securities. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the condensed balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in income from investments held in Trust Account in the accompanying condensed statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. During the period January 1, 2021 to December 31, 2021, the Company did not withdraw any interest income from the Trust Account to pay its tax obligations. On November 9, 2021, the Sponsor requested that the Company extend the date by which the Company has to consummate a Business Combination from November 12, 2021 to February 12, 2022 (the “First Extension”). The First Extension was the first of up to two three-month extensions permitted under the Company’s governing documents. On November 10, 2021, $900,000 ($0.10 per share) was added to the Trust Account for the First Extension of the Company. On February 9, 2022, the Company held an extraordinary general meeting pursuant to which the Company’s shareholders approved extending the date by which the Company had to complete a Business Combination from February 12, 2022 to August 12, 2022 (the “Second Extension”). In connection with the approval of the Second Extension, shareholders elected to redeem an aggregate of 6,326,758 Ordinary Shares. As a result, an aggregate of $64,996,858 (or approximately ($10.27 per share) was released from the Trust Account to pay such shareholders. On August 12, 2022, the Company held an extraordinary general meeting pursuant to which the Company’s shareholders approved extending the date by which the Company has to complete a Business Combination from August 12, 2022 to February 12, 2023 (the “Third Extension”). In connection with the approval of the Third Extension, shareholders elected to redeem an aggregate of 646,617 Ordinary Shares. As a result, an aggregate of $6,660,150 (or approximately $10.30 per share) was released from the Trust Account to pay such shareholders and $202,460 (approximately $0.10 per share) was added to the Trust Account. In connection with the Third Extension, $303,994 (approximately $0.15 per share), plus $835 of applicable interest was added to the Trust Account on January 24, 2023. On February 9, 2023, the Company held an extraordinary general meeting in lieu of an annual meeting pursuant to which the Company’s shareholders approved extending the date by which the Company had to complete a Business Combination from February 12, 2023 to August 12, 2023 (the “Fourth Extension”). In connection with the approval of the Fourth Extension, shareholders elected to redeem an aggregate of 1,172,247 Class A ordinary shares. As a result, an aggregate of $12,554,008 (or approximately $10.71 per share) was released from the Trust Account to pay such shareholders. In connection with the Fourth Extension, $213,595 (approximately $0.10 per share) was added to the Trust Account as of June 30, 2023. Fair Value Measurements The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the Financial Accounting Standards Board (“FASB”) ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheets. Convertible Promissory Note The Company accounts for its convertible promissory note under ASC 815, Derivatives and Hedging (“ASC 815”). Under 815-15-25, the election can be at the inception of a financial instrument to account for the instrument under the fair value option under ASC 825. The Company has made such election for its convertible promissory note. Using fair value option, the convertible promissory note is required to be recorded at its initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the note are recognized as non-cash change in the fair value of the convertible promissory note in the statements of operations. The fair value of the conversion feature of the note was valued utilizing the Monte Carlo model. Derivative warrant liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued share purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. The Company accounts for its 479,000 Private Warrants and 450,000 Representative’s Warrants issued in connection with its Initial Public Offering as derivative warrant liabilities in accordance with ASC 815-40. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statements of operations. The fair value of warrants issued by the Company in connection with the Public Offering and Private Placement has been estimated using Monte-Carlo simulations at each measurement date. Offering Costs Associated with IPO The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A - “Expenses of Offering”. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Public Offering and that were charged to shareholders’ equity upon the completion of the IPO. Accordingly, on December 31, 2020, offering costs totaling $3,246,381 have been charged to shareholders’ equity (consisting of $1,575,000 of underwriting fee, the fair value of the representative’s warrants of $424,270, the fair value of representative’s shares $653,250 and $593,861 of other cash offering costs). Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ deficit. The Company’s ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. On February 9, 2022, the Company held an extraordinary general meeting pursuant to which the Company’s shareholders approved extending the date by which the Company had to complete a Business Combination from February 12, 2022 to August 12, 2022. In connection with the approval of the extension, shareholders elected to redeem an aggregate of 6,326,758 Ordinary Shares. As a result, an aggregate of $64,996,858 (or approximately $10.27 per share) was released from the Trust Account to pay such shareholders. On August 12, 2022, the Company held an extraordinary general meeting pursuant to which the Company’s shareholders approved extending the date by which the Company has to complete a Business Combination from August 12, 2022 to February 12, 2023. In connection with the approval of the extension, shareholders elected to redeem an aggregate of 646,617 Ordinary Shares. As a result, an aggregate of $6,660,150 (or approximately $10.30 per share) was released from the Trust Account to pay such shareholders. On February 9, 2023, the Company held an extraordinary general meeting in lieu of an annual meeting pursuant to which the Company’s shareholders approved extending the date by which the Company had to complete a Business Combination from February 12, 2023 to August 12, 2023. In connection with the approval of the extension, shareholders elected to redeem an aggregate of 1,172,247 Class A ordinary shares. As a result, an aggregate of $12,554,008 (or approximately $10.71 per share) was released from the Trust Account to pay such shareholders. Accordingly, as of June 30, 2023 and December 31, 2022, 854,378 and 2,026,625 shares of Class A ordinary shares subject to possible redemption, respectively, are presented at redemption value as temporary equity outside of the shareholders’ deficit section of the Company’s balance sheets. As of June 30, 2023 and December 31, 2022, the Class A ordinary shares reflected in the balance sheets are reconciled in the following table: Gross proceeds $ 90,000,000 Less: Ordinary share issuance costs (3,246,381 ) Plus: Fair value adjustment of carrying value to redemption value 5,705,929 Contingently redeemable ordinary shares at December 31, 2021 $ 92,459,548 Less: Redemption of 6,326,758 shares (64,996,858 ) Redemption of 646,617 shares (6,660,150 ) Plus: Fair value adjustment of carrying value to redemption value 516,615 Contingently redeemable ordinary shares at December 31, 2022 21,319,155 Less: Redemption of 1,172,247 shares (12,554,008 ) Plus: Fair value adjustment of carrying value to redemption value 752,578 Contingently redeemable ordinary shares at June 30, 2023 $ 9,517,725 Net Loss Per Ordinary Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net loss per ordinary share is computed by dividing the net loss by the weighted average number of ordinary shares outstanding for each of the periods. Accretion associated with the redeemable shares of Class A ordinary shares is excluded from earnings per share as the redemption value approximates fair value. Changes in fair value are not considered a dividend of the purposes of the numerator in the earnings per share calculation. The calculation of diluted loss per ordinary share does not consider the effect of the warrants and rights issued in connection with the IPO since the exercise of the warrants and rights are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. The warrants and rights are exercisable for 6,137,400 shares of Class A ordinary shares in the aggregate. Three Months Ended Six Months Ended 2023 2022 2023 2022 Ordinary shares subject to possible redemption Numerator: Net loss allocable to Class A ordinary shares subject to possible redemption $ (64,278 ) $ (903,128 ) $ (203,239 ) $ (3,785,344 ) Denominator: Weighted Average Redeemable Class A Ordinary shares, Basic and Diluted 854,378 2,673,242 1,132,868 4,036,466 Basic and Diluted net loss per share, Redeemable Class A Ordinary shares $ (0.08 ) $ (0.34 ) $ (0.18 ) $ (0.94 ) Non-Redeemable Ordinary shares Numerator: Net loss allocable to Non-redeemable Class A and Class B ordinary shares not subject to redemption $ (210,957 ) $ (947,304 ) $ (503,044 ) $ (2,629,553 ) Denominator: Weighted Average Non-Redeemable Class A and Class B Ordinary shares, Basic and Diluted 2,804,000 2,804,000 2,804,000 2,804,000 Basic and diluted net loss per share, ordinary shares $ (0.08 ) $ (0.34 ) $ (0.18 ) $ (0.94 ) Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s unaudited condensed financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2023 and December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s interim condensed financial statements. The Company’s management does not expect the total amount of unrecognized tax benefits will materially change over the next twelve months. Recently Adopted Accounting Standards In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. As a smaller reporting company, ASU 2020-06 is effective January 1, 2024, for fiscal years beginning after December 15, 2023, and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company adopted ASU 2020-06 on January 1, 2021. Adoption of the ASU did not impact the Company’s financial position, results of operations or cash flows. The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying unaudited condensed financial statements.

Initial Public Offering

Initial Public Offering	6 Months Ended
	Jun. 30, 2023
Initial Public Offering [Abstract]
INITIAL PUBLIC OFFERING	NOTE 3. INITIAL PUBLIC OFFERING Pursuant to the IPO, the Company sold 9,000,000 Units at a purchase price of $10.00 per unit. Each unit consists of one share of Class A ordinary shares, one-half warrant to purchase one share of Class A ordinary shares (“Public Warrants”), and one right (“Rights”). Each Public Warrant will entitle the holder to purchase one share of Class A ordinary shares at a price of $11.50 per share, subject to adjustment. Each Public Warrant will become exercisable on the later of the completion of the initial Business Combination or 12 months from the closing of the IPO and will expire five

Private Placement

Private Placement	6 Months Ended
	Jun. 30, 2023
Private Placement [Abstract]
PRIVATE PLACEMENT	NOTE 4. PRIVATE PLACEMENT Simultaneously with the closing of the IPO, the Sponsor and I-Bankers purchased an aggregate of 414,000 Private Units and 65,000 Private Units, respectively, for an aggregate of 479,000 Private Units at a price of $10.00 per Private Unit, for an aggregate purchase price of $4,790,000, in a private placement. A portion of the proceeds from the private placement was added to the proceeds from the IPO held in the Trust Account. Each Private Unit is identical to the Units sold in the IPO, except that warrants that are part of the Private Placement Units (“Private Warrants”) are not redeemable by the Company so long as they are held by the original holders or their permitted transferees. In addition, for as long as the warrants that are part of the Private Placement Units are held by I-Bankers or its designees or affiliates, they may not be exercised after five years from the effective date of the Registration Statement. The Company’s Sponsor, officers, and directors have agreed to (i) waive their redemption rights with respect to their founder shares, private shares, and public shares in connection with the completion of the Company’s initial Business Combination, (ii) waive their redemption rights with respect to the founder shares, private shares, and public shares in connection with a shareholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to redeem 100% of its public shares if the Company does not complete its initial Business Combination within the Combination Period or (B) with respect to any other provision relating to shareholders’ rights or pre-initial Business Combination activity and (iii) waive their rights to liquidating distributions from the Trust Account with respect to their founder shares if the Company fails to complete its initial Business Combination the Combination Period. In addition, the Company’s Sponsor, officers, and directors have agreed to vote any founder shares, private shares, and public shares held by them and any public shares purchased during or after the IPO (including in open market and privately negotiated transactions) in favor of the Company’s initial business combination.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 5. RELATED PARTY TRANSACTIONS Founder Shares In September 2020, the Sponsor subscribed 2,875,000 shares of the Company’s Class B ordinary shares for $25,000, or approximately $0.01 per share, in connection with formation. On November 9, 2020, the Sponsor surrendered an aggregate of 287,500 founder shares, which were cancelled, resulting in an aggregate of 2,587,500 founder shares outstanding and held by the Sponsor. The founder shares included an aggregate of up to 337,500 shares subject to forfeiture if the over-allotment option was not exercised by the underwriters in full. On December 24, 2020, 337,500 shares were forfeited as the over-allotment option was not exercised by the underwriters. On March 7, 2023, the Company issued an aggregate of 1,685,152 of the Company’s Class A ordinary shares to the Sponsor upon the conversion of an equal number of the Company’s Class B ordinary shares held by the Sponsor. On March 7, 2023, the Company also issued an aggregate of 564,847 of the Company’s Class A ordinary shares to Sea Otter Securities, Stitching Juridisch Eigendom Mint Tower Arbitrage Fund, Feis Equities, LLC, Yakira Capital Management, Inc., Yakira Enhanced Offshore Fund, Yakira Partners LP, MAP 136 Segregated Portfolio, and Meteora Capital Partners, LP (collectively, “the Backstop Investors) upon the conversion of an equal number of the Company’s Class B ordinary shares held by the Backstop Investors. As a result, as of June 30, 2023, there was 1 Class B ordinary share issued and outstanding. Promissory Notes—Related Party In September 2020, the Company issued an unsecured promissory note to the Sponsor, pursuant to which the Company may borrow up to an aggregate principal amount of $300,000 to be used for a portion of the expenses of the IPO. This loan is non-interest bearing, unsecured and due at the earlier of September 30, 2021, or the closing of the IPO. As of November 12, 2020, the Sponsor had loaned to the Company an aggregate of $177,591 under the promissory note to pay for formation costs and a portion of the expenses of the IPO. The note was repaid in full in connection with the closing of the initial public offering, and as of June 30, 2023 and December 31, 2022 respectively, no amounts were outstanding. Borrowings under this note are no longer available. On August 25, 2022, the Company issued a promissory note (the “August 2022 Note”) in the aggregate principal amount of up to $202,460 to the Sponsor, pursuant to which the Extension Funds will be deposited into the Company’s trust account for each Class A ordinary share of the Company that was not redeemed in connection with the extension of the Company’s termination date from August 12, 2022 to February 12, 2023. The principal amount of the August 2022 Note may be drawn down in three equal amounts and the balance of the August 2022 Note is payable by the Company on the earlier of the consummation of the Business Combination or the date of the liquidation of the Company. As of June 30, 2023, $202,460 was outstanding under the August 2022 Note. On October 6, 2022, the Company issued a promissory note in the principal amount of up to $500,000 to the Sponsor (the “October 2022 Note”). The Note was issued in connection with advances the Sponsor may make in the future to the Company for working capital expenses. The note bears no interest and is due and payable upon the earlier to occur of (i) the date on which the Company consummates its initial business combination and (ii) the date that the winding up of the Company is effective. As of June 30, 2023, $500,000 was outstanding under the October 2022 Note. On November 16, 2022, the Company issued a promissory note in the principal amount of up to $303,994 to the Sponsor (the “November 2022 Note”), pursuant to which the Extension Funds will be deposited into the Company’s trust account for each unredeemed Class A ordinary share of the Company that was not redeemed in connection with the extension of the Company’s termination date from August 12, 2022 to February 12, 2023. The principal amount of the November 2022 Note may be drawn down in three equal payments of $101,331 per withdrawal between the 12th and 19th of each November and December 2022 and January 2023 and the balance of the November 2022 Note is payable by the Company on the earlier of the consummation of the Business Combination or the date of the liquidation of the Company. As of June 30, 2023, there was $303,994 outstanding under the November 2022 Note. On January 10, 2023, the Company issued a promissory note (the “January 2023 Note”) in the principal amount of up to $450,000 to the Sponsor for working capital purposes. The Note bears no interest and is due and payable upon the earlier to occur of (i) the date on which the Company consummates its initial business combination and (ii) the date that the winding up of the Company is effective. As of June 30, 2023 there was $276,006 outstanding on the January 2023 Note. On February 14, 2023, the Company issued a non-interest-bearing promissory note in the aggregate amount of up to $256,313 to the Sponsor (the “February 2023 Note”), pursuant to which the Extension Funds will be deposited into the Company’s trust account for each unredeemed Class A ordinary share of the Company that was not redeemed in connection with the extension of the Company’s termination date from February 12, 2023 to August 12, 2023. As of June 30, 2023, $170,877 was drawn on the note. On April 25, 2023, the Company issued a promissory note (the “April 2023 Note”) in the principal amount of up to $175,000 to the Sponsor for working capital purposes. The Note bears no interest and is due and payable upon the earlier to occur of (i) the date on which the Company consummates its initial business combination and (ii) the date that the winding up of the Company is effective. As of June 30, 2023 there was $175,000 outstanding on the April 2023 Note. On June 26, 2023, the Company issued a promissory note (the “June 2023 Note”) in the principal amount of up to $250,000 to the Sponsor for working capital purposes. The Note bears no interest and is due and payable upon the earlier to occur of (i) the date on which the Company consummates its initial business combination and (ii) the date that the winding up of the Company is effective. As of June 30, 2023 there was $20,000 outstanding on the June 2023 Note. Convertible Promissory Notes - Related Party Extension Loans and Working Capital Loans On November 9, 2021, the Company’s board of directors approved the first extension of the date by which the Company has to consummate a Business Combination from November 12, 2021, to February 12, 2022. In connection with the extension, the Sponsor deposited into the Trust Account $0.10 for each of the 9,000,000 shares issued in the Initial Public Offering, for a total of $900,000. The Company issued the Sponsor an interest bearing unsecured promissory note (the “November 2021 Note”) in the principal amount of $900,000 which is payable by the Company upon the earlier of the consummation of the Business Combination or the liquidation of the Company on or before February 12, 2023 (unless such date is extended by the Company’s board of directors). Simple interest will accrue on the unpaid principal balance of the November 2021 Note at the rate of 4% per annum based on 365 days a year. The November 2021 Note may be repaid in cash or convertible into units consisting of one ordinary share, one right exchangeable into one-tenth of one ordinary share, and one warrant exercisable for one-half of one ordinary share at $11.50 per share equal to (x) the portion of the principal amount of and accrued interest under the November 2021 Note being converted divided by (y) $10.00 rounded up to the nearest whole number of units. As of June 30, 2023 and December 31, 2022, $900,000 was outstanding under the November 2021 Note. For the period ended June 30, 2023 and December 31, 2022, $58,981 and $41,129 of interest was accrued on the November 2021 Note, respectively. On February 13, 2022, the Company issued a promissory note (the “February 2022 Note”) in the principal amount of up to $750,000 to American Physicians LLC. The February 2022 Note was issued in connection with advances the Sponsor has made to the Company for working capital expenses. The February 2022 Note bears no interest and is due and payable upon the earlier to occur of (i) the date on which the Company consummates its initial Business Combination and (ii) the date that the winding up of the Company is effective. At the election of the Sponsor, up to $600,000 of the unpaid principal amount of the February 2022 Note may be converted into units of the Company, each unit consisting of one Class A share of the Company, one right exchangeable into one-tenth of one Class A ordinary share and one warrant exercisable for one-half of one Class A ordinary share of the Company upon the consummation of an initial Business Combination (the “Conversion Units”), equal to (x) the portion of the principal amount of the February 2022 Note being converted, divided by (y) $10.00 rounded up to the nearest whole number of units. The Conversion Units are identical to the units issued by the Company to the Sponsor in a private placement in connection with the Company’s initial public offering. The Conversion Units and their underlying securities are entitled to the registration rights set forth in the February 2022 Note. As of June 30, 2023, $750,000 was outstanding under the February 2022 Note. Changes in the estimated fair value of the November 2021 Note and the February 2022 Note were recognized as non-cash change in the fair value of the convertible promissory note in the statements of operations. Administrative Support Agreement The Company agreed, for a period commencing on November 9, 2020, and ending upon completion of the Company’s Business Combination or its liquidation, to pay the Company’s Sponsor a monthly fee of $10,000 for office space, utilities and secretarial and administrative support. Since the initial public offering, the Company has not made any payments under the agreement and has paid for services rendered and expenses advanced by the Sponsor on an as-needed basis. Effective March 31, 2021, the Company and Sponsor terminated the agreement and agreed to waive any accrued fees from inception. As of June 30, 2023 and December 31, 2022, no fees were due to the Sponsor. The Sponsor, executive officers and directors, or any of their respective affiliates, will be reimbursed for any out-of-pocket expenses incurred in connection with activities on the Company’s behalf such as identifying potential target businesses and performing due diligence on suitable Business Combinations. The Company’s audit committee will review on a quarterly basis expenses incurred and all payments that were made to the Sponsor, officers, directors or their affiliates.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 6. COMMITMENTS AND CONTINGENCIES Registration Rights The holders of the founder shares, private placement warrants, and warrants that may be issued upon conversion of Working Capital Loans will have registration rights to require the Company to register a sale of any of its securities held by them pursuant to a registration rights agreement to be signed prior to or on the effective date of the IPO. These holders will be entitled to make up to three demands, excluding short form registration demands, that the Company registers such securities for sale under the Securities Act. In addition, these holders will have “piggy-back” registration rights to include their securities in other registration statements filed by the Company. Underwriting Agreement On November 12, 2020, the Company issued to the underwriter (and/or its designees) (the “Representative”) 75,000 shares of Class A ordinary shares for $0.01 per share (the “Representative Shares”). The fair value of the Representative Shares was estimated to $653,250 and were treated as underwriters’ compensation and charged directly to shareholders’ equity. The underwriter (and/or its designees) agreed (i) to waive its redemption rights with respect to such shares in connection with the completion of the initial Business Combination and (ii) to waive its rights to liquidating distributions from the Trust Account with respect to such shares if the Company fails to complete its initial Business Combination within the Combination Period. In addition, the Company issued to the Representative a warrant (“Representative’s Warrant) to purchase up to 450,000 Class A ordinary shares. Such warrants will not be redeemable for as long as they are held by the Representative, and they may not be exercised after five years from the Effective Date of the registration statement. Except as described above, the warrants are identical to those underlying the units offered by in the IPO. The Company initially estimated the fair value of the Representative’s Warrants at $424,270 using the Monte Carlo simulation model. As of December 31, 2021, the fair value of the Representative’s Warrant granted to the underwriters is estimated to be $107,779 using the following assumptions: (1) expected volatility of 6.5%, (2) risk-free interest rate of 1.29% and (3) expected life of 5.39 years. The expected volatility was determined by the Company based on the historical volatilities of a set of comparative special purpose acquisition companies (“SPAC”), and the risk-fee interest rate was determined by reference to the U.S. Treasury yield curve in effect for time period equals to the expected life of the Representative’s Warrant. On November 12, 2020, the underwriters were paid a cash underwriting discount of 1.75% of the gross proceeds of the Initial Public Offering, or $1,575,000. Business Combination Marketing Agreement The Company engaged the Representative as an advisor in connection with its Business Combination to (i) assist the Company in preparing presentations for each potential Business Combination; (ii) assist the Company in arranging meetings with its shareholders, including making calls directly to shareholders, to discuss each potential Business Combination and each potential target’s attributes and providing regular market feedback, including written status reports, from these meetings and participate in direct interaction with shareholders, in all cases to the extent legally permissible; (iii) introduce the Company to potential investors to purchase the Company’s securities in connection with each potential Business Combination; and assist the Company with the preparation of any press releases and filings related to each potential Business Combination or target. Pursuant to the business combination marketing agreement, the Representative is not obligated to assist the Company in identifying or evaluating possible acquisition candidates. Pursuant to the Company’s agreement with the Representative, an advisory fee of 2.75% of the gross proceeds of the IPO, or $2,475,000 will be payable to the Representative at the closing of the Company’s Business Combination. Open Market Purchases Our sponsor entered into an agreement in accordance with the guidelines of Rule 10b5-1 under the Exchange Act, to place limit orders, through ED&F Man Capital Markets Inc., an independent broker-dealer registered under Section 15 of the Exchange Act which is not affiliated with us nor part of the underwriting or selling group, to purchase an aggregate of up to 3,750,000 of our rights in the open market at market prices, and not to exceed $0.20 per right during the period commencing on the later of (i) December 10, 2020, the date separate trading of the rights commenced or (ii) sixty calendar days after the end of the “restricted period” under Regulation M, continuing until the date that was the earlier of (a) November 9, 2021 and (b) the date that we announced that we had entered into a definitive agreement in connection with our initial Business Combination, or earlier in certain circumstances as described in the limit order agreement. The limit orders required such members of our sponsor to purchase any rights offered for sale (and not purchased by another investor) at or below a price of $0.20, until the earlier of (x) the expiration of the buyback period or (y) the date such purchases reach 3,750,000 rights in total. Our sponsor would not have any discretion or influence with respect to such purchases and will not be able to sell or transfer any rights purchased in the open market pursuant to such agreements until following the consummation of a Business Combination. It was intended that the broker’s purchase obligation would be subject to applicable law, including Regulation M under the Exchange Act, which may prohibit or limit purchases pursuant to the limit order agreement in certain circumstances. I-Bankers also agreed to purchase up to 1,250,000 of our rights in the open market at market prices not to exceed $0.20 per right, on substantially similar terms as our sponsor. The obligations to make any such purchases expired on November 9, 2021, and as of June 30, 2023, no limit orders were placed by our sponsor or I-Bankers. Business Combination Agreement On December 5, 2022, EDOC Acquisition Corp., a Cayman Islands exempted corporation (together with its successors, “Edoc”), entered into a Business Combination Agreement (the “Business Combination Agreement”) with Australian Oilseeds Investments Pty Ltd., an Australian proprietary company (the “AOI”), Australian Oilseeds Holdings Limited, upon execution of a joinder agreement to become party to the Business Combination Agreement (a “Joinder”), a to-be-formed Cayman Islands exempted company (“Pubco”), AOI Merger Sub, upon execution of a Joinder, a to-be-formed Cayman Islands exempted company and a wholly-owned subsidiary of Pubco (“Merger Sub”), American Physicians LLC, a Delaware limited liability company (“Purchaser Representative”), in the capacity as the Purchaser Representative thereunder, Gary Seaton, in his capacity as the representative for the Sellers (as defined below) in accordance with the terms and conditions of the Business Combination Agreement (the “Seller Representative”) and each of the holders of AOI’s outstanding capital shares named on Annex I thereto (the “Primary Sellers”), as amended from time to time to include subsequent parties that execute and deliver to Edoc, Pubco and AOI a Joinder (the “Joining Sellers”), and the holders of AOI’s outstanding capital shares who are bound by the provisions of the Business Combination Agreement pursuant the drag-along rights set forth in AOI’s memorandum and articles of association (the “Drag-Along Sellers”, and collectively with the Joining Sellers, the “Sellers”). Pursuant to the Business Combination Agreement, subject to the terms and conditions set forth therein, at the closing of the transactions contemplated by the Business Combination Agreement (the “Closing”), (a) Edoc will merge with and into Merger Sub, with Edoc continuing as the surviving entity (the “Merger”), and with holders of Edoc securities receiving substantially identical securities of Pubco, and (b) immediately prior to the Merger, Pubco will acquire all of the issued and outstanding ordinary shares of AOI (the “Purchased Shares”) from the Sellers in exchange for ordinary shares of Pubco, with AOI becoming a wholly-owned subsidiary of Pubco (the “Share Exchange”, and together with the Merger and the other transactions contemplated by the Business Combination Agreement, the “Transactions”). On March 31, 2023, the Company, AOI, Pubco, Merger Sub, and the Purchaser Representative entered into that certain First Amendment to the Business Combination Agreement (the “First Amendment”), pursuant to which the Business Combination Agreement was amended to add, as a closing condition, that upon the closing of the transactions contemplated by the Business Combination Agreement, the Company shall have cash and cash equivalents, including fund remaining in the Company’s trust account (after giving effect to the completion and payment of the redemption) and the proceeds of any PIPE Investment, prior to giving effect to the payment of the Company’s unpaid expenses or liabilities, of at least equal to $10,000,000.

Warrants and Rights

Warrants and Rights	6 Months Ended
	Jun. 30, 2023
Warrants and Rights [Abstract]
WARRANTS AND RIGHTS	NOTE 7. WARRANTS AND RIGHTS Warrants The warrants will become exercisable on the later of 12 months from the closing of the IPO or upon completion of its initial Business Combination and will expire five years after the completion of the Company’s initial Business Combination, at 5:00 p.m., Eastern Time, or earlier upon redemption or liquidation. In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. The Company will not be obligated to deliver any Class A ordinary shares pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the Class A ordinary shares underlying the warrants is then effective and a prospectus is current. No warrant will be exercisable, and the Company will not be obligated to issue Class A ordinary shares upon exercise of a warrant unless Class A ordinary shares issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the share of Class A ordinary shares underlying such unit. The Company may call the warrants for redemption (excluding the private warrants, and any outstanding Representative’s Warrants, and any warrants underlying units issued to the Sponsor, initial shareholders, officers, directors or their affiliates in payment of Working Capital Loans made to the Company), in whole and not in part, at a price of $0.01 per warrant: ● at any time while the warrants are exercisable, ● upon not less than 30 days’ prior written notice of redemption to each warrant holder, ● if, and only if, the reported last sale price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30-trading day period ending on the third trading business day prior to the notice of redemption to warrant holders, and ● if, and only if, there is a current registration statement in effect with respect to the issuance of the Class A ordinary shares underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day until the date of redemption. If the Company calls the warrants for redemption as described above, the management will have the option to require any holder that wishes to exercise its warrant to do so on a “cashless basis.” If the management takes advantage of this option, all holders of warrants would pay the exercise price by surrendering their warrants for that number of shares of Class A ordinary shares equal to the quotient obtained by dividing (x) the product of the number of shares of Class A ordinary shares underlying the warrants, multiplied by the excess of the “fair market value” (defined below) over the exercise price of the warrants by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the Class A ordinary shares for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. Rights The Company will not issue fractional shares in connection with an exchange of rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed in accordance with the applicable provisions of the Cayman Islands law. As a result, the holders of the rights must hold rights in multiples of 10 in order to receive shares for all of the holders’ rights upon closing of a Business Combination. If the Company is unable to complete an initial Business Combination within the required time period and the Company liquidates the funds held in the Trust Account, holders of rights will not receive any of such funds with respect to their rights, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such rights, and the rights will expire worthless. Further, there are no contractual penalties for failure to deliver securities to the holders of the rights upon consummation of an initial Business Combination. Additionally, in no event will the Company be required to net cash settle the rights. Accordingly, the rights may expire worthless.

Shareholders_ Deficit

Shareholders’ Deficit	6 Months Ended
	Jun. 30, 2023
Shareholders’ Deficit [Abstract]
SHAREHOLDERS’ DEFICIT	NOTE 8. SHAREHOLDERS’ DEFICIT Preferred Shares Class A Ordinary Shares Class B Ordinary Shares The Company’s initial shareholders have agreed not to transfer, assign or sell 50% its founder shares until the earlier to occur of (i) six months after the date of the consummation of the initial Business Combination or (ii) the date on which the closing price of the Company’s Class A ordinary shares equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after the initial Business Combination and the remaining 50% of the founder shares may not be transferred, assigned or sold until six months after the date of the consummation of the initial Business Combination, or earlier, in either case, if, subsequent to the initial Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the shareholders having the right to exchange their shares for cash, securities or other property. The Class B ordinary share will automatically convert into the Company’s Class A ordinary shares at the time of its initial Business Combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein. In the case that additional Class A ordinary shares, or equity-linked securities, are issued or deemed issued in excess of the amounts offered in the IPO and related to the closing of the initial Business Combination, the ratio at which the Class B ordinary share shall convert into Class A ordinary shares will be adjusted (unless the holders of a majority of the outstanding Class B ordinary shares agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of Class A ordinary shares issuable upon conversion of the Class B ordinary share will equal, in the aggregate, on an as-converted basis, 20% of the sum of the total number of ordinary shares outstanding upon the completion of the IPO plus all Class A ordinary shares and equity-linked securities issued or deemed issued in connection with the initial Business Combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the initial Business Combination or any private placement-equivalent units issued to the Sponsor or its affiliates upon conversion of loans made to the Company). Holders of the Class A ordinary shares and the holder of the Class B ordinary share will vote together as a single class on all matters submitted to a vote of the Company’s shareholders, with each share of ordinary shares entitling the holder to one vote.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 9. FAIR VALUE MEASUREMENTS Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 820 “Fair Value Measurements and Disclosures” (“ASC 820”) defines fair value, the methods used to measure fair value and the expanded disclosures about fair value measurements. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between the buyer and the seller at the measurement date. In determining fair value, the valuation techniques consistent with the market approach, income approach and cost approach shall be used to measure fair value. ASC 820 establishes a fair value hierarchy for inputs, which represent the assumptions used by the buyer and seller in pricing the asset or liability. These inputs are further defined as observable and unobservable inputs. Observable inputs are those that buyer and seller would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs that the buyer and seller would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels based on the inputs as follows: Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment. Level 2 – Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets and liabilities, or (iv) inputs that are derived principally from or corroborated by market through correlation or other means. Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The fair value of the Company’s certain assets and liabilities, which qualify as financial instruments under ASC 820, approximates the carrying amounts represented in the balance sheets as of June 30, 2023 and December 31, 2022. The fair values of cash and cash equivalents, prepaid assets, accounts payable and accrued expenses are estimated to approximate the carrying values as of June 30, 2023 and December 31, 2022, due to the short maturities of such instruments. The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at June 30, 2023 and December 31, 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Description: Level June 30, Level December 31, Assets: U.S. Money Market Funds Held in Trust Account 1 $ — 1 $ 21,319,155 Liabilities: Warrant liability—Private Warrants 3 6,706 3 20,623 Warrant liability—Representative’s Warrants 3 — 3 2,634 Convertible Promissory Notes 3 1,660,943 3 1,512,412 Investment Held in Trust Account As of June 30, 2023 and December 31, 2022, investments in the Company’s Trust Account consisted of $9,517,725 and $21,319,155 in cash and U.S. Money Market funds, respectively. There were no transfers between Levels 1, 2 or 3 during the period ended June 30, 2023 and December 31, 2022. Level 1 instruments include investments in money markets and Treasury securities. The Company uses inputs such as actual trade data, benchmark yields, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments. Warrant Liability The Private Warrants and Representative’s Warrants are accounted for as liabilities pursuant to ASC 815-40 and are measured at fair value as of each reporting period. Changes in the fair value of the Warrants are recorded in the statements of operations each period. The Private Warrants and Representative’s Warrants were valued using a Montel Carlo simulation model, which is considered to be a Level 3 fair value measurement. Inherent in an options pricing model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its ordinary shares based on historical volatility that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates to remain at zero. There were no transfers between Levels 1, 2 or 3 during the period ended June 30, 2023 and December 31, 2022. The following table provides quantitative information regarding Level 3 fair value measurements for Private Warrants as of June 30, 2023 and December 31, 2022. The Representative’s Warrants were valued using similar information, except for strike price which is at $12. June 30, December 31, Exercise price $ 11.50 $ 11.50 Share price $ 11.07 $ 10.50 Volatility de minimis 8.0 % Expected life 0.82 0.70 Risk-free rate 5.42 % 4.75 % Dividend yield - % - % The following table presents a summary of the changes in the fair value of the Private Warrants and Representative’s Warrants, a Level 3 liability, measured on a recurring basis. Private Representative’s Warrant Fair value as of December 31, 2022 $ 20,623 $ 2,634 $ 23,257 Change in fair value (1) (9,657 ) (2,634 ) (12,291 ) Fair value as of March 31, 2023 $ 10,966 $ - $ 10,966 Change in fair value (1) (4,260 ) - (4,260 ) Fair value as of June 30, 2023 $ 6,706 $ - $ 6,706 (1) Represents the non-cash gain on change in valuation of the Private Warrants and Representative’s Warrants and is included in Change in fair value of warrant liability on the statements of operations. Convertible Promissory Notes The convertible promissory notes were valued using a Monte Carlo simulation model, which is considered to be a Level 3 fair value measurement. The estimated fair value of the Convertible Promissory Notes was based on the following significant inputs: June 30, December 31, Risk-free interest rate 5.39 % 4.43 % Time to Expiration (in years) 0.17 0.26 Expected volatility 4.1 % 4.0 % Dividend yield 0.00 % 0.00 % Stock Price $ 11.21 $ 10.63 Probability of transaction 85.0 % 85.0 % The following table presents the changes in the fair value of the Level 3 Convertible Promissory Note: Fair value as of December 31, 2021 $ 975,324 Proceeds received through Convertible Promissory Note 750,000 Interest accrued 36,102 Proceeds in excess of fair value (109,078 ) Change in fair value (139,936 ) Fair value as of December 31, 2022 1,512,412 Interest accrued at 4% per annum based on 365 in a year 8,876 Change in fair value 38,414 Fair value as of March 31, 2023 $ 1,559,702 Interest accrued at 4% per annum based on 365 in a year 8,976 Change in fair value 92,265 Fair value as of June 30, 2023 $ 1,660,943 There were no transfers in or out of Level 3 from other levels in the fair value hierarchy during the period ended June 30, 2023 for the Convertible Promissory Note.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10. SUBSEQUENT EVENTS The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the interim unaudited condensed financial statements were issued. Based upon this review, other than stated below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the interim unaudited condensed financial statements. On July 12, 2023, the Company drew $30,000 on the June 2023 Note. On July 14, 2023, the Company paid an extension payment of $42,719 to the Trust account.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC on January 24, 2023, which contains the audited financial statements and notes thereto.
Emerging Growth Company	Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging the growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s unaudited condensed financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts or mutual fund accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. As of June 30, 2023 and December 31, 2022, the Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.
Use of Estimates	Use of Estimates The preparation of unaudited condensed financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities during the reporting period and the reported amounts of expenses during the reporting period. One of the more significant accounting estimates included in these unaudited condensed financial statements is the determination of the fair value of the warrant liabilities as well as the fair value of the convertible notes. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of June 30, 2023 and December 31, 2022.
Investment Held in Trust Account	Investment Held in Trust Account As of June 30, 2023, all of the assets held in the Trust account were held in cash. As of December 31, 2022, substantially all of assets held in the Trust Account were held in money market funds which are invested primarily in U.S. Treasury securities. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the condensed balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in income from investments held in Trust Account in the accompanying condensed statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. During the period January 1, 2021 to December 31, 2021, the Company did not withdraw any interest income from the Trust Account to pay its tax obligations. On November 9, 2021, the Sponsor requested that the Company extend the date by which the Company has to consummate a Business Combination from November 12, 2021 to February 12, 2022 (the “First Extension”). The First Extension was the first of up to two three-month extensions permitted under the Company’s governing documents. On November 10, 2021, $900,000 ($0.10 per share) was added to the Trust Account for the First Extension of the Company. On February 9, 2022, the Company held an extraordinary general meeting pursuant to which the Company’s shareholders approved extending the date by which the Company had to complete a Business Combination from February 12, 2022 to August 12, 2022 (the “Second Extension”). In connection with the approval of the Second Extension, shareholders elected to redeem an aggregate of 6,326,758 Ordinary Shares. As a result, an aggregate of $64,996,858 (or approximately ($10.27 per share) was released from the Trust Account to pay such shareholders. On August 12, 2022, the Company held an extraordinary general meeting pursuant to which the Company’s shareholders approved extending the date by which the Company has to complete a Business Combination from August 12, 2022 to February 12, 2023 (the “Third Extension”). In connection with the approval of the Third Extension, shareholders elected to redeem an aggregate of 646,617 Ordinary Shares. As a result, an aggregate of $6,660,150 (or approximately $10.30 per share) was released from the Trust Account to pay such shareholders and $202,460 (approximately $0.10 per share) was added to the Trust Account. In connection with the Third Extension, $303,994 (approximately $0.15 per share), plus $835 of applicable interest was added to the Trust Account on January 24, 2023. On February 9, 2023, the Company held an extraordinary general meeting in lieu of an annual meeting pursuant to which the Company’s shareholders approved extending the date by which the Company had to complete a Business Combination from February 12, 2023 to August 12, 2023 (the “Fourth Extension”). In connection with the approval of the Fourth Extension, shareholders elected to redeem an aggregate of 1,172,247 Class A ordinary shares. As a result, an aggregate of $12,554,008 (or approximately $10.71 per share) was released from the Trust Account to pay such shareholders. In connection with the Fourth Extension, $213,595 (approximately $0.10 per share) was added to the Trust Account as of June 30, 2023.
Fair Value Measurements	Fair Value Measurements The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the Financial Accounting Standards Board (“FASB”) ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheets.
Convertible Promissory Note	Convertible Promissory Note The Company accounts for its convertible promissory note under ASC 815, Derivatives and Hedging (“ASC 815”). Under 815-15-25, the election can be at the inception of a financial instrument to account for the instrument under the fair value option under ASC 825. The Company has made such election for its convertible promissory note. Using fair value option, the convertible promissory note is required to be recorded at its initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the note are recognized as non-cash change in the fair value of the convertible promissory note in the statements of operations. The fair value of the conversion feature of the note was valued utilizing the Monte Carlo model.
Derivative warrant liabilities	Derivative warrant liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued share purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. The Company accounts for its 479,000 Private Warrants and 450,000 Representative’s Warrants issued in connection with its Initial Public Offering as derivative warrant liabilities in accordance with ASC 815-40. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statements of operations. The fair value of warrants issued by the Company in connection with the Public Offering and Private Placement has been estimated using Monte-Carlo simulations at each measurement date.
Offering Costs Associated with IPO	Offering Costs Associated with IPO The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A - “Expenses of Offering”. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Public Offering and that were charged to shareholders’ equity upon the completion of the IPO. Accordingly, on December 31, 2020, offering costs totaling $3,246,381 have been charged to shareholders’ equity (consisting of $1,575,000 of underwriting fee, the fair value of the representative’s warrants of $424,270, the fair value of representative’s shares $653,250 and $593,861 of other cash offering costs).
Class A Ordinary Shares Subject to Possible Redemption	Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ deficit. The Company’s ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. On February 9, 2022, the Company held an extraordinary general meeting pursuant to which the Company’s shareholders approved extending the date by which the Company had to complete a Business Combination from February 12, 2022 to August 12, 2022. In connection with the approval of the extension, shareholders elected to redeem an aggregate of 6,326,758 Ordinary Shares. As a result, an aggregate of $64,996,858 (or approximately $10.27 per share) was released from the Trust Account to pay such shareholders. On August 12, 2022, the Company held an extraordinary general meeting pursuant to which the Company’s shareholders approved extending the date by which the Company has to complete a Business Combination from August 12, 2022 to February 12, 2023. In connection with the approval of the extension, shareholders elected to redeem an aggregate of 646,617 Ordinary Shares. As a result, an aggregate of $6,660,150 (or approximately $10.30 per share) was released from the Trust Account to pay such shareholders. On February 9, 2023, the Company held an extraordinary general meeting in lieu of an annual meeting pursuant to which the Company’s shareholders approved extending the date by which the Company had to complete a Business Combination from February 12, 2023 to August 12, 2023. In connection with the approval of the extension, shareholders elected to redeem an aggregate of 1,172,247 Class A ordinary shares. As a result, an aggregate of $12,554,008 (or approximately $10.71 per share) was released from the Trust Account to pay such shareholders. Accordingly, as of June 30, 2023 and December 31, 2022, 854,378 and 2,026,625 shares of Class A ordinary shares subject to possible redemption, respectively, are presented at redemption value as temporary equity outside of the shareholders’ deficit section of the Company’s balance sheets. As of June 30, 2023 and December 31, 2022, the Class A ordinary shares reflected in the balance sheets are reconciled in the following table: Gross proceeds $ 90,000,000 Less: Ordinary share issuance costs (3,246,381 ) Plus: Fair value adjustment of carrying value to redemption value 5,705,929 Contingently redeemable ordinary shares at December 31, 2021 $ 92,459,548 Less: Redemption of 6,326,758 shares (64,996,858 ) Redemption of 646,617 shares (6,660,150 ) Plus: Fair value adjustment of carrying value to redemption value 516,615 Contingently redeemable ordinary shares at December 31, 2022 21,319,155 Less: Redemption of 1,172,247 shares (12,554,008 ) Plus: Fair value adjustment of carrying value to redemption value 752,578 Contingently redeemable ordinary shares at June 30, 2023 $ 9,517,725
Net Loss Per Ordinary Share	Net Loss Per Ordinary Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net loss per ordinary share is computed by dividing the net loss by the weighted average number of ordinary shares outstanding for each of the periods. Accretion associated with the redeemable shares of Class A ordinary shares is excluded from earnings per share as the redemption value approximates fair value. Changes in fair value are not considered a dividend of the purposes of the numerator in the earnings per share calculation. The calculation of diluted loss per ordinary share does not consider the effect of the warrants and rights issued in connection with the IPO since the exercise of the warrants and rights are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. The warrants and rights are exercisable for 6,137,400 shares of Class A ordinary shares in the aggregate. Three Months Ended Six Months Ended 2023 2022 2023 2022 Ordinary shares subject to possible redemption Numerator: Net loss allocable to Class A ordinary shares subject to possible redemption $ (64,278 ) $ (903,128 ) $ (203,239 ) $ (3,785,344 ) Denominator: Weighted Average Redeemable Class A Ordinary shares, Basic and Diluted 854,378 2,673,242 1,132,868 4,036,466 Basic and Diluted net loss per share, Redeemable Class A Ordinary shares $ (0.08 ) $ (0.34 ) $ (0.18 ) $ (0.94 ) Non-Redeemable Ordinary shares Numerator: Net loss allocable to Non-redeemable Class A and Class B ordinary shares not subject to redemption $ (210,957 ) $ (947,304 ) $ (503,044 ) $ (2,629,553 ) Denominator: Weighted Average Non-Redeemable Class A and Class B Ordinary shares, Basic and Diluted 2,804,000 2,804,000 2,804,000 2,804,000 Basic and diluted net loss per share, ordinary shares $ (0.08 ) $ (0.34 ) $ (0.18 ) $ (0.94 )
Income Taxes	Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s unaudited condensed financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2023 and December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s interim condensed financial statements. The Company’s management does not expect the total amount of unrecognized tax benefits will materially change over the next twelve months.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. As a smaller reporting company, ASU 2020-06 is effective January 1, 2024, for fiscal years beginning after December 15, 2023, and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company adopted ASU 2020-06 on January 1, 2021. Adoption of the ASU did not impact the Company’s financial position, results of operations or cash flows. The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying unaudited condensed financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2023
Summary of Significant Accounting Policies [Abstract]
Schedule of Class A Ordinary Shares Reflected in the Balance Sheets	As of June 30, 2023 and December 31, 2022, the Class A ordinary shares reflected in the balance sheets are reconciled in the following table: Gross proceeds $ 90,000,000 Less: Ordinary share issuance costs (3,246,381 ) Plus: Fair value adjustment of carrying value to redemption value 5,705,929 Contingently redeemable ordinary shares at December 31, 2021 $ 92,459,548 Less: Redemption of 6,326,758 shares (64,996,858 ) Redemption of 646,617 shares (6,660,150 ) Plus: Fair value adjustment of carrying value to redemption value 516,615 Contingently redeemable ordinary shares at December 31, 2022 21,319,155 Less: Redemption of 1,172,247 shares (12,554,008 ) Plus: Fair value adjustment of carrying value to redemption value 752,578 Contingently redeemable ordinary shares at June 30, 2023 $ 9,517,725
Schedule of Basic and Diluted Loss Per Ordinary Share	Changes in fair value are not considered a dividend of the purposes of the numerator in the earnings per share calculation. The calculation of diluted loss per ordinary share does not consider the effect of the warrants and rights issued in connection with the IPO since the exercise of the warrants and rights are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. The warrants and rights are exercisable for 6,137,400 shares of Class A ordinary shares in the aggregate. Three Months Ended Six Months Ended 2023 2022 2023 2022 Ordinary shares subject to possible redemption Numerator: Net loss allocable to Class A ordinary shares subject to possible redemption $ (64,278 ) $ (903,128 ) $ (203,239 ) $ (3,785,344 ) Denominator: Weighted Average Redeemable Class A Ordinary shares, Basic and Diluted 854,378 2,673,242 1,132,868 4,036,466 Basic and Diluted net loss per share, Redeemable Class A Ordinary shares $ (0.08 ) $ (0.34 ) $ (0.18 ) $ (0.94 ) Non-Redeemable Ordinary shares Numerator: Net loss allocable to Non-redeemable Class A and Class B ordinary shares not subject to redemption $ (210,957 ) $ (947,304 ) $ (503,044 ) $ (2,629,553 ) Denominator: Weighted Average Non-Redeemable Class A and Class B Ordinary shares, Basic and Diluted 2,804,000 2,804,000 2,804,000 2,804,000 Basic and diluted net loss per share, ordinary shares $ (0.08 ) $ (0.34 ) $ (0.18 ) $ (0.94 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Measurements (Tables) [Line Items]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at June 30, 2023 and December 31, 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Description: Level June 30, Level December 31, Assets: U.S. Money Market Funds Held in Trust Account 1 $ — 1 $ 21,319,155 Liabilities: Warrant liability—Private Warrants 3 6,706 3 20,623 Warrant liability—Representative’s Warrants 3 — 3 2,634 Convertible Promissory Notes 3 1,660,943 3 1,512,412
Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements	The following table provides quantitative information regarding Level 3 fair value measurements for Private Warrants as of June 30, 2023 and December 31, 2022. The Representative’s Warrants were valued using similar information, except for strike price which is at $12. June 30, December 31, Exercise price $ 11.50 $ 11.50 Share price $ 11.07 $ 10.50 Volatility de minimis 8.0 % Expected life 0.82 0.70 Risk-free rate 5.42 % 4.75 % Dividend yield - % - % June 30, December 31, Risk-free interest rate 5.39 % 4.43 % Time to Expiration (in years) 0.17 0.26 Expected volatility 4.1 % 4.0 % Dividend yield 0.00 % 0.00 % Stock Price $ 11.21 $ 10.63 Probability of transaction 85.0 % 85.0 %
Schedule of Fair Value of Warrant Liabilities	The following table presents a summary of the changes in the fair value of the Private Warrants and Representative’s Warrants, a Level 3 liability, measured on a recurring basis. Private Representative’s Warrant Fair value as of December 31, 2022 $ 20,623 $ 2,634 $ 23,257 Change in fair value (1) (9,657 ) (2,634 ) (12,291 ) Fair value as of March 31, 2023 $ 10,966 $ - $ 10,966 Change in fair value (1) (4,260 ) - (4,260 ) Fair value as of June 30, 2023 $ 6,706 $ - $ 6,706 (1) Represents the non-cash gain on change in valuation of the Private Warrants and Representative’s Warrants and is included in Change in fair value of warrant liability on the statements of operations.
Convertible Promissory Notes [Member]
Fair Value Measurements (Tables) [Line Items]
Schedule of Changes in the Fair Value of the Level 3 Convertible Promissory Note	The following table presents the changes in the fair value of the Level 3 Convertible Promissory Note: Fair value as of December 31, 2021 $ 975,324 Proceeds received through Convertible Promissory Note 750,000 Interest accrued 36,102 Proceeds in excess of fair value (109,078 ) Change in fair value (139,936 ) Fair value as of December 31, 2022 1,512,412 Interest accrued at 4% per annum based on 365 in a year 8,876 Change in fair value 38,414 Fair value as of March 31, 2023 $ 1,559,702 Interest accrued at 4% per annum based on 365 in a year 8,976 Change in fair value 92,265 Fair value as of June 30, 2023 $ 1,660,943

Description of Organization, _2

Description of Organization, Business Operations, and Going Concern (Details) - USD ($)

3 Months Ended

6 Months Ended

12 Months Ended

Feb. 12, 2023

Feb. 09, 2023

Aug. 12, 2022

Feb. 09, 2022

Nov. 10, 2021

Nov. 12, 2020

Mar. 31, 2023

Jun. 30, 2023

Dec. 31, 2020

Jun. 26, 2023

Apr. 25, 2023

Feb. 14, 2023

Jan. 10, 2023

Nov. 16, 2022

Oct. 06, 2022

Aug. 25, 2022

Feb. 13, 2022

Description of Organization, Business Operations, and Going Concern (Details) [Line Items]

Initial public offering (in Shares)

479,000

Units per share (in Dollars per share)

$ 0.15

$ 10.71

$ 0.1

$ 0.1

Number of units (in Shares)

65,000

Number of purchase share (in Shares)

3,750,000

Market price per right (in Dollars per share)

$ 0.2

Cash underwriting fee

$ 1,575,000

Fair value of warrants

424,270

Fair value of representatives shares value

653,250

Other cost offering cost

593,861

Amount of trust account

$ 900,000

$ 213,595

Interest was added to the Trust Account

$ 303,994

Applicable interest added to trust account

$ 835

Class A ordinary shares (in Shares)

1,172,247

Amount released from the trust account

$ 12,554,008

Aggregate fair market value, percentage

80%

Business combination, description

The decision as to whether the Company will seek shareholder approval of a proposed initial Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The shareholders will be entitled to redeem their shares for a pro rata portion of the amount then on deposit in the Trust Account (initially approximately $10.17 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations).

Net tangible assets

$ 5,000,001

Redeem public shares, percentage

100%

Public per share (in Dollars per share)

$ 10.17

Per share reduction in the value of trust accounts (in Dollars per share)

$ 10.17

Business combination agreement , description

The total consideration to be paid by Pubco to the Sellers for the Purchased Shares shall be an aggregate number of Pubco ordinary shares (the “Exchange Shares”) with an aggregate value (the “Exchange Consideration”) equal to, without duplication, (i) $190,000,000, plus (or minus if negative) (ii) AOI’s net working capital less a target net working capital of $4,000,000, minus (iii) the aggregate amount of any outstanding indebtedness, net of cash and cash equivalents, of AOI and its subsidiaries, and minus (iv) the amount of any unpaid transaction expenses of AOI, with each Pubco ordinary share to be issued to the Sellers valued at $10.00.

Unpaid expenses

$ 10,000,000

Operating bank account

$ 9,558

Working capital deficit

5,777,448

Withdrawal of fair value note

900,000

Accrued interest

58,981

Fair value of the note outstanding

958,981

Outstanding amount

750,000

Fair market value note outstanding

$ 701,962

Initial Public Offering [Member]

Description of Organization, Business Operations, and Going Concern (Details) [Line Items]

Initial public offering (in Shares)

9,000,000

Units per share (in Dollars per share)

$ 0.1

$ 10.17

$ 10

Transaction cost

$ 3,246,381

Fair value of representatives shares value

$ 653,250

Net proceeds

$ 91,530,000

Amount of trust account

$ 202,460

Trust account per public share (in Dollars per share)

$ 10

Private Placement [Member]

Description of Organization, Business Operations, and Going Concern (Details) [Line Items]

Initial public offering (in Shares)

479,000

Units per share (in Dollars per share)

$ 10

Class A Ordinary Shares [Member]

Description of Organization, Business Operations, and Going Concern (Details) [Line Items]

Price per share (in Dollars per share)

$ 0.0001

Sponsor [Member]

Description of Organization, Business Operations, and Going Concern (Details) [Line Items]

interest-bearing convertible promissory amount

$ 900,000

Principal amount

$ 750,000

Aggregate amount

$ 250,000

$ 175,000

$ 256,313

$ 450,000

$ 303,994

$ 500,000

$ 202,460

Non-interest-Bearing Promissory Note 1 [Member]

Description of Organization, Business Operations, and Going Concern (Details) [Line Items]

Outstanding amount

$ 202,460

Non-interest-Bearing Promissory Note 2 [Member]

Description of Organization, Business Operations, and Going Concern (Details) [Line Items]

Outstanding amount

500,000

Non-interest-Bearing Promissory Note 3 [Member]

Description of Organization, Business Operations, and Going Concern (Details) [Line Items]

Outstanding amount

303,994

Non-interest-Bearing Promissory Note 4 [Member]

Description of Organization, Business Operations, and Going Concern (Details) [Line Items]

Outstanding amount

276,006

Non-interest-Bearing Promissory Note 5 [Member]

Description of Organization, Business Operations, and Going Concern (Details) [Line Items]

Outstanding amount

170,876

Non-interest-Bearing Promissory Note 6 [Member]

Description of Organization, Business Operations, and Going Concern (Details) [Line Items]

Outstanding amount

175,000

Non-interest-Bearing Promissory Note 7 [Member]

Description of Organization, Business Operations, and Going Concern (Details) [Line Items]

Outstanding amount

$ 20,000

Business Combination [Member]

Description of Organization, Business Operations, and Going Concern (Details) [Line Items]

Business combination, description

In connection with the approval of the extension, shareholders elected to redeem an aggregate of 646,617 Class A ordinary shares. As a result, an aggregate of $6,660,150 (or approximately $10.30 per share) was released from the Trust Account to pay such shareholders.

In connection with the approval of the extension, shareholders elected to redeem an aggregate of 6,326,758 Class A ordinary shares. As a result, an aggregate of $64,996,858 (or approximately $10.27 per share) was released from the Trust Account to pay such shareholders.

Outstanding voting securities percentage

50%

I-Banker [Member]

Description of Organization, Business Operations, and Going Concern (Details) [Line Items]

Number of purchase share (in Shares)

1,250,000

Market price per right (in Dollars per share)

$ 0.2

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)			6 Months Ended	12 Months Ended
	Aug. 12, 2022	Nov. 10, 2021	Jun. 30, 2023	Dec. 31, 2020	Dec. 31, 2022
Summary of Significant Accounting Policies (Details) [Line Items]
Federal depository insurance coverage limit			$ 250,000
Trust account		$ 900,000
Trust account per share (in Dollars per share)		$ 0.1
Aggregate of ordinary shares (in Shares)			6,326,758
Aggregate of trust account to pay shareholders			$ 64,996,858
Aggregate price per share (in Dollars per share)			$ 10.27
Aggregate an ordinary shares (in Shares)	646,617		646,617
Investment held in trust account description			As a result, an aggregate of $6,660,150 (or approximately $10.30 per share) was released from the Trust Account to pay such shareholders and $202,460 (approximately $0.10 per share) was added to the Trust Account. In connection with the Third Extension, $303,994 (approximately $0.15 per share), plus $835 of applicable interest was added to the Trust Account on January 24, 2023. On February 9, 2023, the Company held an extraordinary general meeting in lieu of an annual meeting pursuant to which the Company’s shareholders approved extending the date by which the Company had to complete a Business Combination from February 12, 2023 to August 12, 2023 (the “Fourth Extension”). In connection with the approval of the Fourth Extension, shareholders elected to redeem an aggregate of 1,172,247 Class A ordinary shares. As a result, an aggregate of $12,554,008 (or approximately $10.71 per share) was released from the Trust Account to pay such shareholders. In connection with the Fourth Extension, $213,595 (approximately $0.10 per share) was added to the Trust Account as of June 30, 2023.
Class A ordinary shares (in Shares)			1,172,247
Private warrants (in Shares)			479,000
Offering costs				$ 3,246,381
Underwriting fee				1,575,000
Fair value of representatives warrants				424,270
Fair value of representative's shares value			$ 653,250
Other cash offering costs				593,861
Share price (in Dollars per share)			$ 11.07		$ 10.5
Aggregate amount	$ 6,660,150
Price per share (in Dollars per share)	$ 10.3
Aggregate amount			$ 12,554,008
IPO [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Representative's Warrants issued			$ 450,000
Fair value of representative's shares value				$ 653,250
Share price (in Dollars per share)			$ 10
Class A Ordinary Shares [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Aggregate of ordinary shares (in Shares)			6,326,758
Aggregate of trust account to pay shareholders			$ 64,996,858
Share price (in Dollars per share)			$ 10.27
Class A ordinary shares subject to possible redemption (in Shares)			854,378		2,026,625
Aggregate class A ordinary shares (in Shares)			6,137,400
Class A Ordinary Shares Subject to Possible Redemption [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Share price (in Dollars per share)			$ 10.71
Trust Account [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Aggregate of trust account to pay shareholders			$ 213,595
Aggregate price per share (in Dollars per share)			$ 0.1

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of Class A Ordinary Shares Reflected in the Balance Sheets - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Class A Ordinary Shares Reflected in the Balance Sheets [Abstract]
Gross proceeds			$ 90,000,000
Less:
Ordinary share issuance costs			(3,246,381)
Plus:
Fair value adjustment of carrying value to redemption value	$ 752,578	$ 516,615	5,705,929
Contingently redeemable ordinary shares	9,517,725	21,319,155	$ 92,459,548
Less:
Redemption of shares	$ (12,554,008)	(64,996,858)
Redemption of 646,617 shares		$ (6,660,150)

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of Class A Ordinary Shares Reflected in the Balance Sheets (Parentheticals) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Schedule of Class A Ordinary Shares Reflected in the Balance Sheets [Abstract]
Redemption of shares	1,172,247	6,326,758
Redemption of shares		646,617

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Loss Per Ordinary Share - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Numerator:
Net loss allocable to Class A ordinary shares subject to possible redemption	$ (64,278)	$ (903,128)	$ (203,239)	$ (3,785,344)
Redeemable Class A Ordinary Shares [Member]
Denominator:
Weighted Average Ordinary shares, Basic	854,378	2,673,242	1,132,868	4,036,466
Basic net loss per share, Ordinary shares	$ (0.08)	$ (0.34)	$ (0.18)	$ (0.94)
Non-Redeemable Class A and Class B Ordinary Shares [Member]
Denominator:
Weighted Average Ordinary shares, Basic	2,804,000	2,804,000	2,804,000	2,804,000
Basic net loss per share, Ordinary shares	$ (0.08)	$ (0.34)	$ (0.18)	$ (0.94)
Numerator:
Net loss allocable to Non-redeemable Class A and Class B ordinary shares not subject to redemption	$ (210,957)	$ (947,304)	$ (503,044)	$ (2,629,553)

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Loss Per Ordinary Share (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Redeemable Class A Ordinary Shares [Member]
Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Loss Per Ordinary Share (Parentheticals) [Line Items]
Weighted Average Ordinary shares, Diluted	854,378	2,673,242	1,132,868	4,036,466
Diluted net loss per share, Ordinary shares	$ (0.08)	$ (0.34)	$ (0.18)	$ (0.94)
Non-Redeemable Class A and Class B Ordinary Shares [Member]
Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Loss Per Ordinary Share (Parentheticals) [Line Items]
Weighted Average Ordinary shares, Diluted	2,804,000	2,804,000	2,804,000	2,804,000
Diluted net loss per share, Ordinary shares	$ (0.08)	$ (0.34)	$ (0.18)	$ (0.94)

Initial Public Offering (Detail

Initial Public Offering (Details) - $ / shares	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Initial Public Offering (Details) [Line Items]
Sale of stock (in Shares)	479,000
Price per unit	$ 11.07	$ 10.5
Expiration period	5 years
Initial Public Offering [Member]
Initial Public Offering (Details) [Line Items]
Sale of stock (in Shares)	9,000,000
Price per unit	$ 10
Class A Ordinary Shares [Member]
Initial Public Offering (Details) [Line Items]
Price per unit	10.27
Public warrant per share	$ 11.5

Private Placement (Details)

Private Placement (Details)	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Private Placement (Details) [Line Items]
Aggregate of private units	479,000
Aggregate of private unit price (in Dollars per share) | $ / shares	$ 10
Warrants exercised term	5 years
Redeem public shares, percentage	100%
Private Placement [Member]
Private Placement (Details) [Line Items]
Aggregate purchase price (in Dollars) | $	$ 4,790,000
Sponsor [Member]
Private Placement (Details) [Line Items]
Aggregate of sponsor private units	414,000
I-Bankers [Member]
Private Placement (Details) [Line Items]
Aggregate of bankers purchased private units	65,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)

1 Months Ended

Nov. 16, 2022

Nov. 09, 2021

Nov. 12, 2020

Nov. 09, 2020

Sep. 30, 2020

Jun. 30, 2023

Jun. 26, 2023

Apr. 25, 2023

Mar. 07, 2023

Feb. 14, 2023

Jan. 10, 2023

Dec. 31, 2022

Oct. 06, 2022

Aug. 25, 2022

Feb. 13, 2022

Dec. 24, 2020

Related Party Transactions (Details) [Line Items]

Aggregate of founder shares (in Shares)

287,500

Aggregate of founder shares outstanding (in Shares)

2,587,500

Aggregate of shares subject to forfeiture (in Shares)

337,500

Promissory note outstanding amount

$ 20,000

Termination date, description

termination date from August 12, 2022 to February 12, 2023.

Relate party transaction, description

The principal amount of the November 2022 Note may be drawn down in three equal payments of $101,331 per withdrawal between the 12th and 19th of each November and December 2022 and January 2023 and the balance of the November 2022 Note is payable by the Company on the earlier of the consummation of the Business Combination or the date of the liquidation of the Company.

Related party extension loans, description

the Company’s board of directors approved the first extension of the date by which the Company has to consummate a Business Combination from November 12, 2021, to February 12, 2022. In connection with the extension, the Sponsor deposited into the Trust Account $0.10 for each of the 9,000,000 shares issued in the Initial Public Offering, for a total of $900,000. The Company issued the Sponsor an interest bearing unsecured promissory note (the “November 2021 Note”) in the principal amount of $900,000 which is payable by the Company upon the earlier of the consummation of the Business Combination or the liquidation of the Company on or before February 12, 2023 (unless such date is extended by the Company’s board of directors). Simple interest will accrue on the unpaid principal balance of the November 2021 Note at the rate of 4% per annum based on 365 days a year. The November 2021 Note may be repaid in cash or convertible into units consisting of one ordinary share, one right exchangeable into one-tenth of one ordinary share, and one warrant exercisable for one-half of one ordinary share at $11.50 per share equal to (x) the portion of the principal amount of and accrued interest under the November 2021 Note being converted divided by (y) $10.00 rounded up to the nearest whole number of units.

Conversion per share (in Dollars per share)

$ 10

Office rent per month

$ 10,000

Over-Allotment Option [Member]

Related Party Transactions (Details) [Line Items]

Shares subject to forfeiture (in Shares)

337,500

Class B Ordinary Shares [Member]

Related Party Transactions (Details) [Line Items]

Issuance of sponsor shares

$ 25,000

Issuance of price per share (in Dollars per share)

$ 0.01

Aggregate shares issued (in Shares)

564,847

Ordinary share, issued (in Shares)

1

2,250,000

Ordinary share, outstanding (in Shares)

1

2,250,000

Class A Ordinary Shares [Member]

Related Party Transactions (Details) [Line Items]

Aggregate shares issued (in Shares)

1,685,152

Ordinary share, issued (in Shares)

2,803,999

554,000

Ordinary share, outstanding (in Shares)

2,803,999

554,000

Founder Shares [Member]

Related Party Transactions (Details) [Line Items]

Issuance of sponsor shares (in Shares)

2,875,000

Unsecured Promissory Note [Member]

Related Party Transactions (Details) [Line Items]

Issuance of aggregate principal amount

$ 300,000

August 2022 Note [Member]

Related Party Transactions (Details) [Line Items]

Promissory note outstanding amount

$ 202,460

October 2022 Note [Member]

Related Party Transactions (Details) [Line Items]

Promissory note outstanding amount

500,000

November 2022 Note [Member]

Related Party Transactions (Details) [Line Items]

Promissory note outstanding amount

303,994

January 2023 Note [Member]

Related Party Transactions (Details) [Line Items]

Promissory note outstanding amount

276,006

February 2023 Note [Member]

Related Party Transactions (Details) [Line Items]

Issuance of aggregate principal amount

$ 750,000

Promissory note outstanding amount

170,877

November 2021 Note [Member]

Related Party Transactions (Details) [Line Items]

Promissory note outstanding amount

900,000

$ 900,000

Accrued interest

58,981

$ 41,129

February 2022 Note [Member]

Related Party Transactions (Details) [Line Items]

Promissory note outstanding amount

750,000

Sponsor [Member]

Related Party Transactions (Details) [Line Items]

Aggregate of loaned to promissory note to pay for formation and IPO expenses

$ 177,591

Sponsor [Member] | August 2022 Note [Member]

Related Party Transactions (Details) [Line Items]

Issuance of aggregate principal amount

$ 202,460

Sponsor [Member] | October 2022 Note [Member]

Related Party Transactions (Details) [Line Items]

Issuance of aggregate principal amount

$ 500,000

Sponsor [Member] | November 2022 Note [Member]

Related Party Transactions (Details) [Line Items]

Issuance of aggregate principal amount

$ 303,994

Sponsor [Member] | January 2023 Note [Member]

Related Party Transactions (Details) [Line Items]

Issuance of aggregate principal amount

$ 450,000

Sponsor [Member] | February 2023 Note [Member]

Related Party Transactions (Details) [Line Items]

Issuance of aggregate principal amount

$ 256,313

Sponsor [Member] | April 2023 Note [Member]

Related Party Transactions (Details) [Line Items]

Issuance of aggregate principal amount

$ 175,000

Sponsor [Member] | June 2023 Note [Member]

Related Party Transactions (Details) [Line Items]

Issuance of aggregate principal amount

$ 250,000

Sponsor [Member] | February 2022 Note [Member]

Related Party Transactions (Details) [Line Items]

Unpaid principal balance

$ 600,000

April 2023 Note [Member]

Related Party Transactions (Details) [Line Items]

Promissory note outstanding amount

$ 175,000

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)		6 Months Ended	12 Months Ended
	Nov. 12, 2020	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2023
Commitments and Contingencies (Details) [Line Items]
Fair value of representative shares	$ 653,250
Fair value of warrants		$ 424,270
Fair value of warrant granted				$ 107,779
Expected volatility rate			8%	6.50%
Risk-free interest rate		5.42%	4.75%	1.29%
Expected life		9 months 25 days	8 months 12 days	5 years 4 months 20 days
Gross proceeds of initial public offering	$ 1,575,000
Open market purchases, description		Our sponsor entered into an agreement in accordance with the guidelines of Rule 10b5-1 under the Exchange Act, to place limit orders, through ED&F Man Capital Markets Inc., an independent broker-dealer registered under Section 15 of the Exchange Act which is not affiliated with us nor part of the underwriting or selling group, to purchase an aggregate of up to 3,750,000 of our rights in the open market at market prices, and not to exceed $0.20 per right during the period commencing on the later of (i) December 10, 2020, the date separate trading of the rights commenced or (ii) sixty calendar days after the end of the “restricted period” under Regulation M, continuing until the date that was the earlier of (a) November 9, 2021 and (b) the date that we announced that we had entered into a definitive agreement in connection with our initial Business Combination, or earlier in certain circumstances as described in the limit order agreement. The limit orders required such members of our sponsor to purchase any rights offered for sale (and not purchased by another investor) at or below a price of $0.20, until the earlier of (x) the expiration of the buyback period or (y) the date such purchases reach 3,750,000 rights in total.
Number of purchase rights (in Shares)		3,750,000
Market price per rights (in Dollars per share)		$ 0.2
Unpaid expenses					$ 10,000,000
Initial Public Offering [Member]
Commitments and Contingencies (Details) [Line Items]
Cash underwriting discount	1.75%
Percentage of advisory fee		2.75%
Gross proceeds		$ 2,475,000
Class A Ordinary Shares [Member]
Commitments and Contingencies (Details) [Line Items]
Issued of underwriter shares (in Shares)	75,000
Ordinary price per share (in Dollars per share)	$ 0.01
Issuance of representative warrant to purchase (in Shares)		450,000
Sponsor [Member]
Commitments and Contingencies (Details) [Line Items]
Purchase of market shares (in Shares)		1,250,000
Market share price to exceeds (in Dollars per share)		$ 0.2

Warrants and Rights (Details)

Warrants and Rights (Details)	6 Months Ended
	Jun. 30, 2023
Warrants and Rights [Abstract]
Warrants, description	Warrants — Each whole warrant entitles the holder to purchase one share of the Company’s Class A ordinary shares at a price of $11.50 per share, subject to adjustment as discussed herein. In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of its initial Business Combination at an issue price or effective issue price of less than $9.50 per share of Class A ordinary shares (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Company’s Sponsor or its affiliates, without taking into account any founder shares held by the Company’s Sponsor or its affiliates, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the initial Business Combination (such price, the “Market Value”) is below $9.50 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the Market Value, and the $18.00 per share redemption trigger price described below under “Redemption of warrants” will be adjusted (to the nearest cent) to be equal to 180% of the Market Value.
Warrant expire, term	5 years
Private warrants redemption, description	●at any time while the warrants are exercisable,    ●upon not less than 30 days’ prior written notice of redemption to each warrant holder,    ●if, and only if, the reported last sale price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30-trading day period ending on the third trading business day prior to the notice of redemption to warrant holders, and    ●if, and only if, there is a current registration statement in effect with respect to the issuance of the Class A ordinary shares underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day until the date of redemption.

Shareholders_ Deficit (Details)

Shareholders’ Deficit (Details) - USD ($)			1 Months Ended	6 Months Ended
	Mar. 07, 2023	Sep. 30, 2020	Dec. 24, 2020	Jun. 30, 2023	Dec. 31, 2022	Nov. 09, 2020
Shareholders’ Deficit (Details) [Line Items]
Preferred stock, shares authorized				5,000,000	5,000,000
Preferred stock par value (in Dollars per share)				$ 0.0001	$ 0.0001
Ordinary shares description	the Company issued an aggregate of 1,685,152 of the Company’s Class A ordinary shares to the Sponsor upon the conversion of an equal number of the Company’s Class B ordinary shares held by the Sponsor. On March 7, 2023, the Company also issued an aggregate of 564,847 of the Company’s Class A ordinary shares to Sea Otter Securities, Stitching Juridisch Eigendom Mint Tower Arbitrage Fund, Feis Equities, LLC, Yakira Capital Management, Inc., Yakira Enhanced Offshore Fund, Yakira Partners LP, MAP 136 Segregated Portfolio, and Meteora Capital Partners, LP (collectively, “the Backstop Investors”) upon the conversion of an equal number of the Company’s Class B ordinary shares held by the Backstop Investors. As a result, as of June 30, 2023, there was 1 Class B ordinary share issued and outstanding.
Business combination warrants, description				The Company’s initial shareholders have agreed not to transfer, assign or sell 50% its founder shares until the earlier to occur of (i) six months after the date of the consummation of the initial Business Combination or (ii) the date on which the closing price of the Company’s Class A ordinary shares equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after the initial Business Combination and the remaining 50% of the founder shares may not be transferred, assigned or sold until six months after the date of the consummation of the initial Business Combination, or earlier, in either case, if, subsequent to the initial Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the shareholders having the right to exchange their shares for cash, securities or other property.
Class A Ordinary Shares [Member]
Shareholders’ Deficit (Details) [Line Items]
Ordinary shares, shares authorized				500,000,000	500,000,000
Ordinary shares, par value (in Dollars per share)				$ 0.0001	$ 0.0001
Ordinary shares, shares issued				2,803,999	554,000
Ordinary shares, shares outstanding				2,803,999	554,000
Ordinary shares, subject to possible redemption				854,378	2,026,625
Class B Ordinary Shares [Member]
Shareholders’ Deficit (Details) [Line Items]
Ordinary shares, shares authorized				50,000,000	50,000,000
Ordinary shares, par value (in Dollars per share)				$ 0.0001	$ 0.0001
Ordinary shares, issued						2,587,500
Ordinary shares, shares issued				1	2,250,000
Ordinary shares, shares outstanding				1	2,250,000
Ordinary shares, subscribed		2,875,000
Issued ordinary shares (in Dollars)		$ 25,000
Common stock per share (in Dollars per share)		$ 0.01
Aggregate founders shares						287,500
Shares outstanding						2,587,500
Ordinary shares outstanding percentage				20%
Class B Ordinary Shares [Member] | Over-Allotment Option [Member]
Shareholders’ Deficit (Details) [Line Items]
Forfeited shares			337,500
Backstop Investors [Member]
Shareholders’ Deficit (Details) [Line Items]
Ordinary shares, issued	564,847
Sponsor [Member]
Shareholders’ Deficit (Details) [Line Items]
Ordinary shares, issued	1,685,152

Fair Value Measurements (Detail

Fair Value Measurements (Details)	Jun. 30, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($)
Fair Value Measurements (Details) [Line Items]
Strike price (in Dollars per Share) | $ / shares	12
U.S. Money Market Funds [Member]
Fair Value Measurements (Details) [Line Items]
Trust Account | $	$ 9,517,725	$ 21,319,155

Fair Value Measurements (Deta_2

Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Level 1 [Member] | U.S. Money Market Funds Held in Trust Account [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
U.S. Money Market Funds Held in Trust Account		$ 21,319,155
Level 3 [Member] | Warrant liability—Private Warrants [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Convertible Promissory Note	6,706	20,623
Level 3 [Member] | Warrant liability—Representative’s Warrants [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Convertible Promissory Note		2,634
Level 3 [Member] | Convertible Promissory Note [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Convertible Promissory Note	$ 1,660,943	$ 1,512,412

Fair Value Measurements (Deta_3

Fair Value Measurements (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Exercise price (in Dollars per share)	$ 11.5	$ 11.5
Share price (in Dollars per share)	$ 11.07	$ 10.5
Volatility		8%	6.50%
Expected life	9 months 25 days	8 months 12 days	5 years 4 months 20 days
Risk-free rate	5.42%	4.75%	1.29%
Dividend yield
Convertible Promissory Note [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Share price (in Dollars per share)	$ 11.21	$ 10.63
Probability of transaction	85%	85%
Volatility	4.10%	4%
Risk-free rate	5.39%	4.43%
Time to Expiration (in years)	2 months 1 day	3 months 3 days
Dividend yield	0%	0%

Fair Value Measurements (Deta_4

Fair Value Measurements (Details) - Schedule of Fair Value of Warrant Liabilities - USD ($)		3 Months Ended
		Jun. 30, 2023	Mar. 31, 2023
Private Warrants [Member]
Fair Value Measurements (Details) - Schedule of Fair Value of Warrant Liabilities [Line Items]
Fair value as of beginning balance		$ 10,966	$ 20,623
Change in fair value	[1]	(4,260)	(9,657)
Fair value as of the ending balance		6,706	10,966
Representative’s Warrants [Member]
Fair Value Measurements (Details) - Schedule of Fair Value of Warrant Liabilities [Line Items]
Fair value as of beginning balance			2,634
Change in fair value	[1]		(2,634)
Fair value as of the ending balance
Warrant Liability [Member]
Fair Value Measurements (Details) - Schedule of Fair Value of Warrant Liabilities [Line Items]
Fair value as of beginning balance		10,966	23,257
Change in fair value	[1]	(4,260)	(12,291)
Fair value as of the ending balance		$ 6,706	$ 10,966
[1] Represents the non-cash gain on change in valuation of the Private Warrants and Representative’s Warrants and is included in Change in fair value of warrant liability on the statements of operations.

Fair Value Measurements (Deta_5

Fair Value Measurements (Details) - Schedule of Changes in the Fair Value of the Level 3 Convertible Promissory Note - Convertible Promissory Note [Member] - USD ($)	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Fair Value Measurements (Details) - Schedule of Changes in the Fair Value of the Level 3 Convertible Promissory Note [Line Items]
Fair value as of beginning balance	$ 1,559,702	$ 1,512,412	$ 1,512,412	$ 975,324
Proceeds received through Convertible Promissory Note				750,000
Interest accrued				36,102
Proceeds in excess of fair value				(109,078)
Interest accrued at 4% per annum based on 365 in a year	8,976	8,876
Change in fair value	92,265	38,414		(139,936)
Fair value as of the ending balance	$ 1,660,943	$ 1,559,702	$ 1,660,943	$ 1,512,412

Fair Value Measurements (Deta_6

Fair Value Measurements (Details) - Schedule of Changes in the Fair Value of the Level 3 Convertible Promissory Note (Parentheticals) - Convertible Promissory Note [Member]	3 Months Ended
	Jun. 30, 2023	Mar. 31, 2023
Fair Value Measurements (Details) - Schedule of Changes in the Fair Value of the Level 3 Convertible Promissory Note (Parentheticals) [Line Items]
Interest accrued percentage per annum	4%	4%
Interest accrued based year	365 years	365 years

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	Jul. 12, 2023	Jul. 14, 2023
Subsequent Events (Details) [Line Items]
Drew amount	$ 30,000
Trust account		$ 42,719